Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 1/127  CLINICAL STUDY PROTOCOL 
 
A PHASE II, SINGLE -BLIND, RANDOMISED, P LACEBO -CONTROLLED TRIAL  
TO STUDY THE EFFICAC Y AND SAFETY OF  
ANTI -VON WILLEBRAND FACTOR NANOBODY  
ADMINISTERED AS ADJUNCTIVE TREATMENT TO PATIENTS WITH  
ACQUIRED THROMBOTIC THROMBOCYTOPENIC P URPURA  
 
CONFIDENTIAL  
 
CRO code: AYX081PR -AL0081  
Sponsor code: ALX -0681- 2.1/[ADDRESS_557596] number: [ADDRESS_557597]:   ALX-0081, anti -von Willebrand factor Nanobody  
INN: caplacizumab 
Clinical Phase:    Phase II study  
Indication to be studi ed:  Acquired thrombotic thrombocytopenic purpura  
 
Sponsor    Ablynx NV, Technologiepark 21, B -9052 Zwijnaarde, Belgium  
Sponsor’s Contact     
       
       
       
 
[CONTACT_439892]   
        
       
       
 
[INVESTIGATOR_439847] 12.0  
 
Date     24 June 2013  
  
 
 
 
  
This study will be performed in compliance with  the principles of Good Clinical Practice (GCP).  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013

Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013

Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 3/[ADDRESS_557598] read the protocol of study ALX -0681 -2.1/10, version 12.0. I understand the contents 
and intend to comply fully with all requirements and the applicable current local and international regulations and guidelines. No changes will be made without formal authorisation by [CONTACT_439893] a protocol amendment. 
    
Investigator Signature: ______________________________ ___________________ 
Investigator Name 
(block letters):  _________________________ Date  
Institution: _________________________________________ 
  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 4/[ADDRESS_557599] I NFORMATION 
 
Sponsor's Study Manager  
 
Ablynx NV  
Technologiepark 21  
B-9052 Zwijnaarde  
Belgium 
Phone:  +32 (0)9 262 00 00  
Fax: +32 (0)[ADDRESS_557600] Management  
 
  
  
  
  
 
 
   
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013

Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 5/[ADDRESS_557601] INFORMATION  
 
In the event of a serious adverse event, the Investigator will send a faxed report within 24 hours of notification to:  
 
CRO  
 
    
  
     
 
MEDICAL EMERGENCIES  
In the event of a medical emergency the Medical Monitor (CRO) can be contact[CONTACT_439894]:  
 
CRO  
 
 
 
  
 
 
 
 
 
  
 
 
 
   Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013

Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 6/[ADDRESS_557602] OF APPENDICES  ....................................................................................................... 15 
1. STUDY SYNOPSIS ....................................................................................................... 16 
2. BACKGROUND INFORMATI ON .................................................................................. 26 
2.1 Introduction  ........................................................................................................................ 26 
2.1.1  Role of vWF in Platelet Aggregation  ....................................................................... 26 
2.1.2  Role of vWF and vWF Processing in Pathophysiology of TTP  .............................. 26 
2.1.3  Role of vWF in Other Pathologies  .......................................................................... 27 
2.2 ALX-0081, anti -vWF Nanobody  ........................................................................................ 27 
2.3 Nonclinical Study Data  ...................................................................................................... 28 
2.3.1  Pharmacology  ......................................................................................................... 28 
2.3.2  Pharmacokinetics  ................................................................................................... 30 
2.3.3  Toxicology  ............................................................................................................... 31  
2.4 Clinical Experience  ............................................................................................................ 32  
2.4.1  Clinical Trials Supporting ACS Indication  ............................................................... 35 
2.4.2  Clinical Trial Supporting TTP Indication: Phase I Study in Healthy Volunteers  ..... 37 
2.5 Safety/Risk P rofile  ............................................................................................................. 40  
2.5.1  Potential Risks  ........................................................................................................ 40 
2.5.2  Potential Benefits  .................................................................................................... 43 
2.6 Rationale for Dose Selection  ............................................................................................ 47 
3. OBJECTIVES  ................................................................................................................ 48 
4. TRIAL DESIGN ............................................................................................................. 49 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 7/[ADDRESS_557603] Discontinuation or Withdrawal  ................................................................... 56 
5.4.3  Procedure for Handling Withdrawals and Replacements  ....................................... 57 
6. STUDY DRUGS  ............................................................................................................ 58 
6.1 Formulation, Packaging and Labelling  ........................................................................... 58 
6.1.1  Study Drug Formulation  .......................................................................................... 58 
6.1.2  Study Drug Packaging  ............................................................................................ 58 
6.1.3  Study Drug Labelling  .............................................................................................. 59 
6.2 Storage and Stability  ......................................................................................................... 59 
6.3 Study Drug Preparation and Administration  .................................................................. 59 
6.4 Return of Study Drug  ........................................................................................................ 60 
6.5 Drug Accountability  .......................................................................................................... 61  
7. TREATMENT  ................................................................................................................ 62 
7.1 Treatments to be Administered  ........................................................................................ 62 
7.2 Treatment and Dosing Regimen for Study Drug  ............................................................ 62 
7.3 Dose modification due to treatment related AE – clinically relevant bleeding  ........... 64 
7.4 Prior / Concomitant Medication  ....................................................................................... 65 
7.5 Assignment to Treatment  ................................................................................................. 66 
7.6 Management of Overdose ................................................................................................. 66 
7.7 Management of Hypersensitivity Reactions  ................................................................... 67 
7.8 Restrictions  ........................................................................................................................ 67 
7.9 Treatment Compliance  ...................................................................................................... 67 
8. STUDY ASSESSMENTS AND PROCEDURES  ............................................................ 68  
8.1 Description of Study  Days and Schedules of Assessments  ........................................ 68 
8.1.1  Screening and Baseline Measurements  ................................................................. 72 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL  Page 8/127 8.1.2  Treatment Phase  .................................................................................................... 76 
8.1.3  Follow -up ................................................................................................................ 84  
8.1.4  Unscheduled Additional Visit  .................................................................................. 90 
8.1.5  Exacerbation and relapse visits .............................................................................. 91 
8.2 Assessment of Efficacy  .................................................................................................... 91 
8.2.1  Clinical Outcome  ..................................................................................................... 91 
[IP_ADDRESS]  Outcomes of Special Interest  ................................................................ 92 
8.2.2  Pharmacodynamics  ................................................................................................ 93 
8.2.3  Laboratory Markers of Disease............................................................................... 94  
8.3 Assessment of  Safety ....................................................................................................... 94 
8.3.1  Safety Laboratory Monitoring .................................................................................. 94 
8.3.2  Physical Examination and Vital Signs  .................................................................... 96 
8.3.3  Bleeding Events  ...................................................................................................... 97 
8.3.4  Cardiovascular Monitoring  ...................................................................................... 98 
8.3.5  Glasgow Coma Score  ............................................................................................. 98 
8.3.6  Neurocognitive Battery  ........................................................................................... 98 
[IP_ADDRESS]  CNTB  .................................................................................................... 99 
[IP_ADDRESS]  Category Fluency Test ........................................................................ 100 
[IP_ADDRESS]  Letter Fluency Test  ............................................................................. 100 
8.3.7  Adverse Events  ..................................................................................................... 100 
8.3.8  Immunogenicity  ..................................................................................................... 101 
8.4 Pharmacokinetic Assessment  ........................................................................................ 101 
8.4.1  Sampling  ............................................................................................................... 101  
8.4.2  Labelling and Shippi[INVESTIGATOR_439848]  ............................................ 102 
8.4.3  Analytical Assays  .................................................................................................. 102 
8.4.4  Pharmacokinetics  ................................................................................................. 102 
9.SAFETY DEFINITIONS A ND REPORTING REQUIRE MENTS  ................................... 103 
9.1 Adverse Events ................................................................................................................ 103  
9.1.1  Definitions of Adverse Events  ............................................................................... 103 
9.1.2  Definition of Adverse Reaction (AR)  ..................................................................... 104 
9.1.3  Intensity of Adverse Events  .................................................................................. 104 
9.1.4  Classification according to CTCAE ....................................................................... 105 
9.1.5  Relationship to Study Drug  ................................................................................... 105 
9.1.6  Reporting of Adverse Events  ................................................................................ 106 
9.1.7  Follow -up of Adverse Events  ................................................................................ 106 
9.2 Serious Adverse Even ts/Serious Adverse Reaction .................................................... 106 
9.2.1  Definitions  ............................................................................................................. 106  
[IP_ADDRESS]  Serious Adverse Events/Serious Adverse Reaction (SAE/SAR)  ....... 106 
[IP_ADDRESS]  Hospi[INVESTIGATOR_439849]  .............. 107 
[IP_ADDRESS]  Serious Adverse Events Related to Study -mandated Pr ocedures  ..... 107 
[IP_ADDRESS]  Suspected Unexpected Serious Adverse Reaction (S[LOCATION_003]R)  ............ 108 
9.2.2  Reporting of Serious Adverse Events  ................................................................... 108 
[IP_ADDRESS]  Before Study Drug Initiation  ................................................................ 108 
[IP_ADDRESS]  During Study Drug Administration  ...................................................... 108 
[IP_ADDRESS]  After Study Drug Discontinuation ........................................................ 108 
[IP_ADDRESS]  Reporting Procedures by [CONTACT_737]  .......................................... 108 
9.2.3  Follo w-up of Serious Adverse Events  ................................................................... 109 
9.2.4  Reporting Procedures by [CONTACT_439895]  .............................. 109 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL  Page 9/[ADDRESS_557604] of the Study  ......................................................................................... 113 
11.3  Patient Information and Consent ................................................................................... 113 
11.4  Insurance/Liability  ........................................................................................................... 114  
12.GENERAL REGULATIONS,  AGREEMENTS AND ORGANISATIONAL
PROCEDURES  ........................................................................................................... 115 
12.1  Legal Aspects/Declaration of Helsinki  .......................................................................... 115 
12.2  Investigator’s Brochure  .................................................................................................. 115 
12.3  Data Protection  ................................................................................................................ 115  
12.4  Monitoring  ........................................................................................................................ 115 
12.5  Audits and Inspections  ................................................................................................... 116 
12.6  Storage of Study Records in the Investigator’s File  .................................................... 116 
12.7  Costs  ................................................................................................................................. 117 
12.8  Confidentiality  .................................................................................................................. 117  
12.9  The Clinical Study’ s Approval and General Obligation of Notification  ...................... 117 
12.10  Final Report and Publication  .......................................................................................... 117 
13.REFERENCES  ............................................................................................................ 119
14.APPE
NDICES  ............................................................................................................. 122 
14.1  Appendix 1: Declaration of Helsinki  .............................................................................. 122 
14.2  Appendix 2:  Common Terminology for Adverse Events v4.0 (CTCAE)  ..................... 126 
14.3  Appendix 3: Elements of Informed Consent  ................................................................. 126 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL  Page 10 /[ADDRESS_557605] Activated clotting time 
ADA Anti-drug antibody  
ADAMTS13  A disintegrin- like and metalloprotease with thrombospondin repeats 13  
AE Adverse event  
ALT Alanine transaminase 
AP Alkaline phosphatase  
aPTT  Activated partial thromboplastin time 
AR Adverse (drug) reaction  
ASAP  As soon as possible  
AST Aspartate transaminase  
AUC 0-t Area under the plasma concentration vs. time curve up to time t  
AUC 0-[ADDRESS_557606]/Lambda z  
AUC inf Area under the plasma concentration vs. time curve up to infinite  
AUC 0-ι Area under the plasma concentration vs. time curve between dosing intervals  
BED Biologically effective dose  
BMI Body mass index  
BNP Brain natriuretic peptide or B-type natriuretic peptide  
BUN  Blood urea nitrogen  
Ca Calcium  
Cl Chloride  
CL Clearance  
Cmax Maximum observed plasma concentration  
CNTB  Computerised neuropsychological test battery  
CRF Case report form  
CRO  Contract research organisation  
CRP  C-reactive protein
CRT Choice reaction time
CSR  Clinical study report
CTCAE  Common terminology criteria for adverse events
CV Coefficient of variation
d Day
DAP Data analysis plan
DAT Direct antiglobulin test
DIC Disseminated intravascular coagulation
DSMB  Data safety monitoring board
EC Ethics committee
ECG  Electrocardiogram
ELISA  Enzyme -linked immunosorbent assay
FVIII  Coagulation factor VIII
g Gram
GCP  Good clinical practice
GFR  Glomerular filtration rate
GLP Good laboratory practice
GP GlycoproteinDocument ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 11 /127  h Hour  
HBsAg  Surface antigen of the hepatitis B virus  
HBV Hepatitis B virus  
hCG Human chorionic gonadotropin  
HCV  Hepatitis C virus  
HIV Human immunodeficiency virus  
HUS  Haemolytic -uremic syndrome  
i.a. Intra- arterial  
IB Investigator’s Broc hure 
ICH International conference on harmonisation  
IEC Independent ethics committee  
i.m. Intramuscular  
INR International normalised ratio  
IRB Institutional review board 
ITP Immune thrombocytopenic purpura  
ITT Intention- to-treat 
IU International unit 
i.v. Intravenous(ly)  
λz Elimination rate constant  
K Potassium  
kg Kilogram  
LDH Lactate dehydrogenase  
LLN Lower limit of normal 
LMWH  Low molecular weight heparin  
m Month  
MD Multiple dose  
MCH  Mean corpuscular haemoglobin  
MCV  Mean corpuscular volume 
MCHC  Mean corpuscular  haemoglobin concentration  
MedDRA  Medical Dictionary for Regulatory Activities  
Mg Magnesium  
mg Milligram  
min Minute  
mL Millilitre  
µL Microlitre  
mm Millimetre  
MRT  Mean residence time 
MTD  Maximum tolerated dose  
Na Sodium  
NA Not applicable  
NOAEL  No observed adverse effect level  
NSE Neuron specific enolase  
NT-proBNP  N-terminal pro B- type natriuretic peptide or N -terminal pro brain natriuretic peptide 
OLE Open label extension  
PCI Percutaneous coronary intervention  
PD Pharmacodynamics  
PE Plasma exchange  
PK Pharmacokinetics  
PP Per 
protocol  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 12 /127  PT Prothrombin time 
PTT Partial thromboplastin time 
QC Quality control  
RBC  Red blood cells  
RICO  Ristocetin cofactor activity  
RIPA  Ristocetin -induced platelet aggregation  
SAE Serious adverse event  
SAP Statistical analysis plan  
SAR Serious adverse (drug) reaction  
Sβ100 Protein S -100 beta  
s.c. Subcutaneous(ly)  
SD Single dose  
SRT Simple reaction time 
S[LOCATION_003]R  Suspected and unexpected serious adverse reactions  
t1/[ADDRESS_557607] Upper limit of normal 
ULvWF  Ultra large vWF  
VMEM  Visual memory  
vWD  von Willebrand disease  
vWF von Willebrand factor  
Vz Volume of distribution  
WBC  White blood cells  
WFI Water for i njection  
WHO  World health organisation  
WLL/DR  Word list learning and delayed recall  
WLL/SR  Word list learning and selective reminding  
WMEM  Working memory  
 
Nanobody® is a registered trademark of Ablynx NV.  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 13 /[ADDRESS_557608] OF TABLES  
 
Table 1:  Dosage, method of administration and treatment duration.  .............................. 22 
Table 2:  Overview and current status of clinical trials with anti -vWF Nanobody.  ............ 33 
Table 3:  Extent of exposure for anti -vWF Nanobody.  ..................................................... 34 
Table 4:  Safety summary of Phase I trials with i.v. administration of anti -vWF 
Nanobody.  ....................................................................................................... 36 
Table 5:  Dosing schedule for Phase I trial with ALX -0081 by s.c. administration.  ........... 37 
Table 6:  Summary of main PD results (n umber (%) of subjects with event).  .................. 38 
Table 7:  Summary of main safety results (number (%) of subjects with event, both 
related and unrelated events)........................................................................... 39 
Table 8:  Dosage, method of administration and treatment duration.  .............................. 65 
Table 9:  General schedule of study assessments. ......................................................... 70 
Table 10:  Schedule of assessments at screening and baseline measurements.  .............. 75 
Table 11:  Schedule of assessments during treatment phase.  .......................................... 80 
Table 12:  Schedule of assessments during treatment phase in case of exacerbation.  ..... 82 
Table 13:  Schedule of assessments during follow -up. ..................................................... 86 
Table 14:  Schedule of assessments during daily PE for the treatment of a relapse.  ........ 88 
Table 15:  Modified ITP bleeding score. ............................................................................ 97 
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 14 /[ADDRESS_557609] OF FIGURES  
 
Figure 1:  Treatment flow chart.  ....................................................................................... 19 
Figure 2:  Therapeutic window of ALX -0081, ReoPro® and Plavix® in a baboon model.  ... 29 
Figure 3:  Effect of ALX -0081 on platelet adhesion to ULvWF.  ......................................... 30 
Figure 4:  Treatment flow chart.  ....................................................................................... 51 
Figure 5:  Schematic overview of pre- treatment, treatment and follow -up phase.  ............. 69  
 
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 15 /[ADDRESS_557610] OF APPENDICES 
 
14.1  Appendix 1:  Declaration of Helsinki  ................................................................ 122 
14.2  Appendix 2: Common Terminology for Adverse Events v4.0 (CTCAE)  .......... 126 
14.3  Appendix 3: Elements o f Informed Consent  ................................................... 126 
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 16 /127  1. STUDY SYNOPSIS  
 
Study Title  
A Phase II, single- blind, randomised, placebo- controlled trial to study the efficacy and safety 
of anti -von Willebrand factor Nanobody administered as adjunctive treatment  to patients with 
acquired thrombotic thrombocytopenic purpura  
 
Study Number : ALX- 0681- 2.1/10  
 
Study Phase : II 
 
Study Centre and Patients  
This is a multicentre, multinational study in which it is anticipated to include 110 patients with 
acquired thrombotic  thrombocytopenic purpura (TTP) in approximately [ADDRESS_557611], Australia and Northern America.  
This population includes symptomatic patients with acute epi[INVESTIGATOR_439850], requiring treatment with plasma exchange (PE). 
 
Objectives 
 
Primary  
• Reduction of time- to-response, defined by [CONTACT_439896], confirmed at 48 hours after the initial reporting of this response 
 
Secondary (including longer -term disease sequelae)  
• Improvement in number of subjects responding to therapy  
• Reduction in PE procedure- related items  
• Reduction of time to resolution or improvement of signs and symptoms typi[INVESTIGATOR_439851], including blood markers  
• Reduction of number of exacerbations (defined as recurrent thrombocytopenia 
following a response and requiring a re -initiation of daily PE treatment after ≥ 1 day 
but ≤ [ADDRESS_557612] daily PE) and relapses (defined as de novo event of TTP 
that occurs later than [ADDRESS_557613] daily PE)
1,2 
• Improvement of cognitive level at steady state post acute phase  
• Improvement of clinical symptoms and organ function  
• Reduction in mortality within the PE treatment period and within the subsequent study Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 17 /127  drug treatment period (including tapering)  
• Reduction of concomitant treatment -related complications  
• Evaluation of safety and immunogenicity of adjunctive treatment with ALX -0081 
• Determination of pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of 
ALX-0081 in patients with acquired TTP  
 
Endpoints  
 
Primary Endpoint  
 
• Time -to-response, based on the followi ng criteria:  
− Recovery of platelets ≥ 150,000/µL  
− This response must be confirmed at 48 hours after the initial reporting of 
platelet recovery equal to or above 150,000/µL by a de novo  measure of 
platelets  ≥ 150,000/µL and lactate dehydrogenase (LDH) ≤ 2 X upper limit of 
normal (ULN) (i.e. “confirmed platelet response”)  
 Secondary Endpoints  
 All endpoints achieved within 30 day period after end of study drug treatment:  
• Number of subjects with complete remission (defined as confirmed platelet response and absence of exacerbation)
1,2 
• Number of (subjects with) exacerbations of TTP (defined as recurrent 
thrombocytopenia following a confirmed platelet response and requiring a re- initiation 
of daily PE treatment after ≥ 1 day but ≤ [ADDRESS_557614] daily PE), and time to 
first exacerbation of TTP  
• Number of subjects relapsing of TTP (defined as de novo event of TTP that occurs 
later than [ADDRESS_557615] daily PE)  
• Number of daily PE sessions, number of plasma units administered and number of 
days of daily PE  
• Resolution of non -focal neurological symptoms as defined by [CONTACT_439897], measured by a neurocognitive test battery  
• Resolution or improvement (improvement of ≥ 1 grade in the Common Terminology 
Criteria for Adverse Events (CTCAE) v4.0 scale) of TTP -related signs and symptoms 
as captured on physical examination and as adverse events, at complete remission 
and at end of the study drug treatment period (including tapering) (by [CONTACT_439898]: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 18 /127  unique subjects and by [CONTACT_439899] (AEs))  
• Total mortality within the PE treatment period and within the subsequent study drug 
treatment period (including tapering)  
• Incidence of PE treatment -related AEs, such as, but not restricted to: haemorrhage 
from catheter insertion, sepsis, catheter thrombosis, pneumothorax, fluid overload, hypoxia, hypotension, anaphylactoid reactions and transfusion related acute lung injury (TRALI)  
• Incidence and severity of ALX -0081 treatment -emergent AEs and relationship to 
study drug 
• Development of anti -drug antibodies (ADA) ≤ [ADDRESS_557616] study drug treatment  
• PK and PD profile 
 
Tertiary Endpoints  
 
 
  
 
 
  
 
  
 
Study Design 
This is a Phase II multicentre, single -blinded, parallel design, randomised, placebo- controlled 
study.  
 
After confirmation of eligibility to study participation, subjects will be randomised in a ratio of 1:1 to either receive ALX- 0081 or placebo as adjunctive therapy to PE ( Figure 1 ). 
  
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013

Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 19 /127   
 
 
Figure 1: Treatment flow chart.  
First PE on study: see section 4.2  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 20 /[ADDRESS_557617] intravenous (i.v.) bolus of 10 mg ALX -0081 or placebo via push 
injection within 6h, but not later than 15 minutes prior to the initiation of PE  on study (which 
can either be the very first PE session, if the subject was randomised prior to the initiation of 
PE, or the second PE session, if the subject was randomised after one, single PE session; 
see section 4.2). This first PE  on study  is followed by [CONTACT_6567] (s.c.) administration of 
10 mg study drug.  
Subsequently daily s.c. administrations of 10 mg ALX -0081 ( Table 1) or placebo will follow 
each PE session for the duration of PE (including tapering and PE given for exacerbations) and once daily for [ADDRESS_557618] PE (including tapering) ( Table 1). The 
maximum total daily dose of study drug is 10 mg when administered in conjunction with PE 
(20 mg only in case twice daily PE sessions are needed) and [ADDRESS_557619] PE (including tapering). Study drug administration will continue in case of re- initiation of PE for an exacerbation of TTP, with a maximum total treatment duration 
limited to [ADDRESS_557620] administration of study drug.   
At ≤ [ADDRESS_557621], safety assessments and assessments of 
response/relapse, re -treatment and study medication dose modification will be assessed at 
each local site laboratory.  
 
An independent Data Safety Monitoring Board (DSMB) will monitor accruing safety data during the study (SAEs on an ongoing basis and ‘early safety look’ when [ADDRESS_557622] completed treatment with study drug) and will 
make recommendations on continuation of the study as appropriate. An interim analysis for safety with formal stoppi[INVESTIGATOR_439852] [ADDRESS_557623] 
been treated, and will make a recommendation on study continuation or discontinuation. No 
review of efficacy data by [CONTACT_439900].   
Planned Sample Size  
It is anticipated to include 110 patients with acquired TTP.  
Study Period 
• 30 months recruitment period is anticipated.  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013

Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 21 /127  • [ADDRESS_557624] administration of study drug (until last subject 
completes the 12- month follow -up visit).  
 
Duration of Treatment and Follow -up 
Treatment with study drug will be continuous during the full time interval of PE and for [ADDRESS_557625] PE (including tapering and PE given for exacerbations). Study drug 
administration will continue in case of re- initiation of PE for an exacerbation of TTP, with a 
maximum treatment duration limited to [ADDRESS_557626] administration of study drug.  
 
Study Medication  
 
ALX-0081, anti -von Willebrand factor (vWF) Nanobody  
ALX-0081 is a clear, colourless solution formulated as a solution for injection. It is provided in 
sterile, preservative- free, non- pyrogenic, single -use 2R glass vials with injection stoppers 
and light blue aluminum crimped caps. One vial contains 2.4 mL solution for injection. One mL solution for injection contains as active ingredient 5 mg of ALX -0081 (INN: 
caplacizumab) . 
 Excipi[INVESTIGATOR_439853] (WFI), potassium chloride ( KCl), potassium dihydrogen phosphate 
(KH
2PO 4), disodium monohydrogen phosphate ( Na2HPO 4x2H 2O), sodium chloride (NaCl), 
Glycine, Polysorbate 80  
 Placebo Placebo is provided in 2R glass vials. One vial contains 2.4 mL solution for injection with identical excipi[INVESTIGATOR_439854] -0081.  
 Storage and Stability  
ALX-0081 and placebo are delivered and stored deep frozen at –20°C (± 5°C) in the original 
outer package to be protected from light. Stability studies showed that ALX -0081 is stable at 
-20°C for at least [ADDRESS_557627] not 
be used after the expi[INVESTIGATOR_439855]. 
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 22 /127  Dosage, Method of Administration and Duration 
 
Dosage, method of administration and duration of treatment are summarised in Table 1. 
 
Table 1: Dosage, method of administration and treatment duration.  
First study drug administration is 10 mg as an i.v. bolus, administered by a push injection,  15 
minutes to 6 hours prior to initiation of PE  on study .* This first PE  on study  is followed by 
[CONTACT_6567] (s.c.) administration of 10 mg study drug.  
* As discussed in section 4.2, one PE session prior to randomisation is allowed. In such case, the second PE 
session will be the first PE on study.  
 
S.c. study drug administration during treatment phase with PE  
Frequency of PE  Treatment administrat ion - daily 
1 PE/day  Administer 10 mg study drug within 30 min after end of PE  
2 PEs/day  • For subjects receiving anti -vWF Nanobody: administer 10 mg study 
drug within 30 min after each PE  
• For subjects receiving placebo, maintain a once daily dosing regim en 
Tapering (< 1 PE/day)  Daily administration of 10 mg study drug. On days with PE: within 30 min 
after end of PE; on days without PE at 24 h ( ± 1 h) after previous 
administration  
 
S.c. study drug administration (in hospi[INVESTIGATOR_418906]) for [ADDRESS_557628] PE  (including 
tapering and PE given for exacerbations)*: 10 mg study drug once daily.  
*  As discussed in section 7.2, in case of exacerbation of TTP, standard treatment (PE) should be re- initiated and 
daily administration of study drug continued. The “study drug post -PE” period (for [ADDRESS_557629] 
PE) will recommence once PE is again stopped. Maximum treatment duration with study drug will be limited to 
[ADDRESS_557630] administration of study drug.  
 
If clinically relevant  bleeding* occurs  
• Stop study drug administration and continue PE if clinically indicated and applicable 
• Assess vWF:Ag and Factor VIII (FVIII) levels**. If FVIII < 10%, assess for anti -FVIII antibodies and 
if presence is confirmed, permanently discontinue study drug.  
• If vWF:Ag and/or FVIII levels are at a clinically significant low level, initiate i.v. Haemate- P 50 U/kg 
(or equivalent antihaemophilic factor/vWF complex)  
• i.v. Haemate- P treatment should be discontinued when bleeding has clearly stopped and when 
vWF > 50%  
• Restart study medication at 10 mg daily when bleeding has clearly stopped and when vWF > 50% 
and FVIII levels are within normal range  
*  Clinically relevant bleeding is defined as moderate to severe (including life-threatening) bleeding requi ring 
urgent  medical and/or surgical intervention.  
** FVIII chromogene or other measure of FVIII activity  
 
Criteria for Evaluation  
 
Clinical Outcome  
• Time -to-response of treatment, defined by a recovery of platelets  ≥ 150,000/µL. This 
response must be confirmed at 48 hours after the initial reporting of platelet recovery Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 23 /127  above 150,000/µL by a de novo measure of platelets ≥ 150,000/µL and LDH ≤ [ADDRESS_557631]  
• Number of subjects with complete remission 
• Number of (subjects with) exacerbations  of TTP  and time to first exacerbation of TTP. 
Number of subjects relapsing of TTP, and time to first relapse of TTP  
• Daily PE data, including serious adverse events (SAEs) related to daily PE treatment  
• Neurocognitive function, as measured by a neurocognitive test battery. This test will 
be preceded by [CONTACT_439901]  
• Improvement of organ dysfunction and improvement of TTP related signs and symptoms  
• Total mortality  
• Determination of  biomarkers of TTP including but not limited to disintegrin- like and 
metalloprotease with thrombospondin repeats 13 (ADAMTS13) levels and anti -
ADAMTS13 antibody titres (see also PD assessments) 
 
Safety Assessments  
• Incidence and severity of ALX -0081 treatment -emergent AEs and relationship to 
study drug 
• Monitoring of safety markers during treatment, including, but not limited to: platelet count and platelet activation, FVIII, activated partial thromboplastin time (aPTT), prothrombin time (PT), fibrinogen, haemoglobin, cardiac markers, liver function, RICO  
• Incidence of clinically relevant bleeding 
• Bleeding graded according to the modified immune thrombocytopenic purpura (ITP) Bleeding Score  
• Vital signs (blood pressure, heart rate and body temperature)  
• Cardiovas cular monitoring 
• Glasgow Coma Score  
• Immunogenicity: development of ADA  
 
PK assessment  
Predose plasma concentrations against time will be plotted to demonstrate attainment of steady state.  
The plasma concentration- time data of ALX -[ADDRESS_557632] demographics, laboratory parameter values, 
and other covariates on the pharmacokinetics of ALX -0081 will be explored.  The results of Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 24 /127  the population PK analyses will be reported separately in an independent Modeling and 
Simulation report.  
 
PD assessments  
• RICO (conducted at central lab)  
• vWF, including vWF:Ag and vWF propeptide (conducted at central lab) 
• FVIII chromogene (conducted at central lab)  
 
Inclusion Criteria  
1. 18 years of age or older  
2. Men or women willing to accept an acceptable contraceptive regimen  
3. Patients with clinical diagnosis of TTP  
4. Necessitating PE (one, single PE session prior to randomisation into the study is 
allowed)  
5. Subject accessible to follow -up 
6. Obtained, signed and dated informed consent  
 
Exclusion Criteria  
1. Platelet count greater or equal to 100,000/µL  
2. Severe active infection indicated by [CONTACT_401689] (requirement for pressors with or wi thout 
positive blood cultures)  
3. Clinical evidence of enteric infection with E. coli 0157 or related organism  
4. Anti-phospholipid syndrome  
5. Diagnosis of disseminated intravascular coagulation (DIC)  
6. Pregnancy or breast -feeding 
7. Haematopoietic stem cell or bone marrow transplantation- associated thrombotic 
microangiopathy  
8. Known congenital TTP  
9. Active bleeding or high risk of bleeding 
10. Uncontrolled arterial hypertension  
11. Known chronic treatment with anticoagulant treatment that can not be stopped safely, including but  not limited to:  
• vitamin K antagonists  
• heparin or low molecular weight heparin (LMWH)  
• non-acetyl salicylic acid non- steroidal anti -inflammatory molecules  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 25 /127  12. Severe or life threatening clinical condition other than TTP that would impair 
participation in the tr ial 
13. Subjects with malignancies resulting in a life expectation of less than 3 months  
14. Subjects with known or suspected bone marrow carcinosis  
15. Subjects who cannot comply with study protocol requirements and procedures.  
16. Known hypersensitivity to the active substance or to excipi[INVESTIGATOR_65877] 
17. Severe liver impairment, corresponding to grade 3 toxicity defined by [CONTACT_439902]. For the key liver parameters, this is defined as follows:  
• bilirubin > [ADDRESS_557633] (need to differentiate isolated increase in indirect bilirubin 
due to haemolysis, this is not an exclusion parameter, but disease related)  
• alanine aminotransferase/aspartate aminotransferase (ALT/AST) > [ADDRESS_557634]  
• alkaline phosphatase (AP) > [ADDRESS_557635]  
• gamma glutamyl transpeptidase (GGT) > [ADDRESS_557636]  
18. Severe chronic renal impairment, as defined by [CONTACT_171895] < 30 mL/min 
 
Statistical Methods  
The primary endpoint (i.e. time- to-response of blood markers comprising recovery of 
platelets ≥ 150,000/µL) will be formally assessed by [CONTACT_3553] a survival analysis.  Descriptive 
statistics for efficacy parameters and secondary/tertiary endpoints (including safety, PK and 
PD analysis) will be presented for all available data, using either the intention- to-treat (ITT) 
population, the safety  population, or the per protocol (PP) population. Additional information 
on the study populations that will be included is available in Section 10. A Statistical Analysis 
Plan (SAP) will be prepared before closing the database and will comprise all methods  and 
tests applied for analysis of the data .  
 
Description of Study Days and Schedules of Assessments  
See Table 9 for a general overview of study assessments. Assessments at screening, during 
the treatment phase and during the follow -up phase are listed in Table 10, Table 11 and 
Table 13  in Section 8.1, respectively.  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 26 /127  2. BACKGROUND INFORMATI ON 
 
2.1 Introduction 
 
2.1.1  Role of vWF in Platelet Aggregation  
 
The multimeric plasma protein vWF is essential for recruiting circulating platelets to the 
damaged vessel wall upon vascular injury. This recruitment is mediated through binding of the vWF A1 -domain with the platelet receptor glycoprotein GPIb -IX-V. 
Upon expression by [CONTACT_196717], vWF is secreted into the circulation as ultra- large 
multimers or ultra -large vWF (ULvWF). These multimers are processed into smaller regular 
sized multimers through enzymatic cleavage by [CONTACT_439903]13. In these regular sized multimers of vWF, the GPIb -IX-V platelet receptor binding site in the A1 domain is cryptic 
and will not spontaneously react with platelets. A conformational activation of the GPIb -IX-V 
platelet receptor binding site in the A1 domain is triggered by [CONTACT_439904]. This then results in platelet adhesion and subsequently in 
thrombus formation.  
 
2.1.[ADDRESS_557637] with the platelet receptor GPIb -IX-V. In healthy subjects, these ULvWF multimers are immediately processed into 
regular sized vWF multimers via cleavage by [CONTACT_439903]13. However, in patients with TTP, processing of the ULvWF multimers is impaired, resulting in the persistence of the constitutively active A1 domain of the ULvWF which readily interacts with the GPIb- IX-V 
platelet receptor. This eventually results in formation of  the characteristic blood clots found in 
the TTP patient population.  
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 27 /[ADDRESS_557638] an inactive A1 domain which becomes only “reactivated” for binding the platelet GPIb -IX-V receptor upon 
immobilisation and through a conformational change under shear stress. This “reactivation” of the A1 domain becomes a critical component in the unwanted thrombus formation in patients with coronary heart disease undergoing a percutaneous coronary intervention (PCI) 
procedure. In coronary arteries, blood flow conditions are recognised as high shear, which 
triggers the said conformational change of the A1 domain in regular sized vWF- multimers, 
resulting in platelet adhesion to the injury of the coronary artery vessel wall (caused by [CONTACT_439905]) and subsequent thrombus formation. Therefore, Ablynx also performed 
clinical studies to develop ALX -0081 for the prevention of thrombosis in coronary heart 
disease, and more specifically acute coronary syndrome (ACS).  
 von Willebrand disease  
In von Willebrand disease (vWD), there are 3 kinds of disorders. Type 1 of the disease is 
pertinent when the vWF is quantitatively reduced, but not absent, with a resulting 
symptomatology that consists of non- severe mucosal bleeding or bruising. Type 2 vWD  
concerns patients who carry gene mutations/deletions resulting in qualitatively abnormal vWF. A subcategory of Type 2 patients (Type 2N), have genetic alterations provoking a markedly decreased binding affinity for FVIII. Type 2, with the exception of Type 2N, has variable bleeding, usually mild to moderate and is in general restricted to limited bruising and mucosal bleeding. In Type 3 vWD virtually no vWF is present. In patients with Type 2N and Type 3 vWD the carrier function of vWF for FVIII is compromised. These patients may present with severe bleeding phenotype resembling haemophilia A, mainly provoked by [CONTACT_439906]. In symptomatic patients (i.e. Type 2N and 3) or in cases where clinical 
interventions could lead to an increased bleeding risk (i.e. tooth extraction, surgeries) vWF concentrate is used as therapeutic, stabilising the patient’s bleeding risk and restoring the normal function of vWF/FVIII -mediated haemostasis.  
 
2.[ADDRESS_557639] with vWF in both its active (i.e. functional for Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 28 /127  interaction with GPIb -IX-V as regular size multimers and as ultra- large multimers) and in its 
inactive stage (regular size multimers prior to conformational change of A1 domain). 
Nanobodies are therapeutic proteins based on the smallest functional fragments of heavy chain antibodies, occurring in the Camelidae family. They have a high degree of sequence 
and structural homology to human immunoglobulin VH domains.  
ALX-[ADDRESS_557640] relevant pharmacological, pharmacokinetic and 
toxicological properties of ALX -0081. See the Investigator’s Brochure for full details on the 
nonclinical development of ALX -0081.  
 
2.3.1  Pharmacology  
 
The affinity of ALX -0081 for the vWF A1- domain was estimated with a Biacore assay at 
< 10 pM. The efficacy of ALX -0081 was studied in vitro  and showed that ALX -0081
 is able to 
inhibit platelet adhesion to collagen specifically under high shear conditions and block ristocetin -induced platelet aggregation (RIPA) with a complete inhibition at a concentration of 
~ 0.4 µg/mL.  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 29 /127  ALX-0081 cross- reacts with vWF of baboon, cynomolgus monkey and guinea pig and 
therefore these species are suitable for PD and toxicological studies. In tissue c ross 
reactivity studies using immunohistochemistry on human, cynomolgus monkey and guinea 
pig tissues, no unexpected staining was observed.  
The efficacy and safety of ALX -0081 was investigated in vivo  in a modified Folts’ model for 
stable angina in baboons. In all of the animals tested, the antithrombotic activity of ALX -0081 
was stronger than that observed for Plavix® (clopi[INVESTIGATOR_7745]), Aspi[INVESTIGATOR_248]® (acetylsalicylic acid) and 
Heparin® (heparin). Similar efficacy of ALX -0081 was observed compared to the potent 
antithrombotic drug ReoPro® (Abciximab). The plasma concentration of ALX -0081 in 
baboons required for full inhibition of thrombus formation was between 0.3 and 0.5 μg/mL. A 
bleeding model involving measurement of the amount of blood from a well defined wound in baboons showed less bleeding with ALX -0081 than with Plavix
® or ReoPro® even at doses 
exceeding the effective dose 10- fold. These results clearly demonstrate that the therapeutic 
window of ALX -0081 is much wider compared to the current marketed drugs Plavix® and 
ReoPro® (Figure 2) 
020406080100
1 10 100 1000 [ZIP_CODE] 100000
Dose [ug /kg] Efficacy [%]
024681012141618Surgical bleedingALX-0081 efficacy Reopro efficacy Plavix efficacy
ALX-0081 bleeding Reopro bleeding Plavix bleeding
 
Figure 2: Therapeutic window of ALX -0081, ReoPro® and Plavix® in a baboon model.  
 Efficacy expressed as % inhibition of cyclic flow reductions in a modified Folts’ 
model and safety expressed as n -fold increase bleeding from a well defined 
incision compared to a control level is shown in function of dose administered.  
 
The antithrombotic activity of ALX -0081 in baboons is of short duration (several hours) and it 
can be reversed by [CONTACT_439907], indicating that vWF can be used as an antidote for ALX- 0081.  
Due to the lack of a relevant animal model, no in vivo  efficacy of ALX -0081 to neutralise 
ULvWF was demonstrated. Initial in vitro  data using plasma from TTP patients in flow 
chamber experiments point towards therapeutic potential of ALX -0081 in the TTP setting. In 
these experiments, endothelial cells were stimulated to produce ULvWF strings on their Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 30 /127  surface. These strings support adhesion of platelets even under static and low shear 
conditions ( Figure 3A) . In the presence of normal plasma the ULvWF strings are rapi[INVESTIGATOR_439856]13, whereas in plasma from patients with TTP 
platelet deposition to the vWF strings is retained due to the lack of functional ADAMTS13 (Figure 3B). Importantly, ALX -0081 added to the TTP plasma completely blocks platelet 
deposition ( Figure 3C), thereby [CONTACT_439908] -0081 not only inhibits the regular 
sized vWF multimers but also ULvWF released by [CONTACT_196717]. However, if platelets 
were allowed to form platelet strings prior to ALX -0081 addition, ALX -0081 was not able to 
detach these platelets.
3  
 
Figure 3: Effect of ALX -0081 on platelet adhesion to ULvWF.  
 Images captured from real -time video microscopy: captures of platelets 
perfused over stimulated endothelial cells under conditions of low shear stress 
(300s- 1). Platelets resuspended in buffer (A) or in plasma from TTP patients (B) 
adhere to ULvWF thereby [CONTACT_439909] (red arrows) on the surface of 
endothelial cells. In the presence of plasma from TTP patients, ALX -0081 
completely abolishes the platelet interaction with ULvWF (C).  
 
2.3.[ADDRESS_557641] phase characterised by a 
rapid decline in plasma levels can be described at the higher doses immediately after administration (i.v.) or after peak plasma levels are reached (s.c./intramuscular [i.m.]).  This is 
thought to be caused by [CONTACT_439910] (glomerular filtration). In cross -reactive species this decline is 
followed by a second phase.
4,5 The terminal half -life (t 1/2) of ALX -[ADDRESS_557642], whereas 
unbound drug is excreted via the kidneys.6  
Since excess ALX -0081 over a vWF occupancy ratio of 1 is cleared rapi[INVESTIGATOR_375], trough drug 
concentrations did not increase significantly even upon multiple administrations at high doses in toxicology studies, again pointing towards a low potential for accumulation. Clinical anticipated administration routes are i.v. and s.c. The absolute bioavailability of ALX -0081 
after s.c. administration, in cynomolgus monkey, ranged from 82 to 97% .
7  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 31 /127  2.3.3  Toxicology  
 
Currently, the toxicology program for ALX -0081 consists of single dose (SD) toxicity studies 
both in cynomolgus monkey (i.v. and s.c.) and guinea pig (i.v.), 2- week repeated dose 
toxicity studies in cynomolgus monkey (i.v., s.c.) including safety pharmacology assessment and 13- week repeated dose toxicity studies in guinea pig and cynomolgus monkey with an 8-
week recovery including safety pharmacology and fertility functional assessment. Local tolerance was assessed separately in rabbit.  
 The pi[INVESTIGATOR_439857] 13- week duration in cynomolgus monkey 
and guinea pig as the non- rodent and rodent species, respectively. In both studies, animal s 
were given s.c. 4 times daily doses of ALX -0081 at 6 hour intervals (0, 0.1, 1 or 10 mg/kg per 
dose) for 13 weeks.  
Data obtained during the in life phase show that vWF/FVIII levels were decreased with a non-cumulative pharmacology effect in cynomolgus monkey and guinea pig (FVIII only), with 
a mean maximum decrease from individual baseline of FVIII of 84 % in all dose groups in cynomolgus monkey. The complete data set including recovery phase is under assessment. In guinea pig, FVIII decreases with a mean of 47.0% (preliminary data reported for 13 -week 
toxicity study, raw data without QC).  
Full neutralisation of vWF activity, defined as below the limit of detection, was demonstrated 
by [CONTACT_439911] (PD marker) in both guinea pig and cynomolgus monkey (preliminary data analysis).  
Clinical observations in the 13- week toxicity study in cynomolgus  monkey revealed slight to 
fairly severe haematomas and swellings at the injection sites in a dose- related manner. 
Macroscopic examination at necropsy revealed haemorrhagic s.c. tissue at the injection sites in several ALX -0081 -treated animals of all dose groups. In addition, slightly increased 
bleeding at injection sites was recorded in one male (4 mg/kg/day) and two females (4 and 40 mg/kg/day). The same female at 4 mg/kg/day showed exaggerated menstrual bleeding on 
Day 30 and the same female at 40 mg/kg/day had a nose bleed. All bleeding events were 
described to be related to the pharmacological effect of ALX -0081.  
In the 13- week toxicity study in guinea pig, no ALX -[ADDRESS_557643] of ALX -0081.  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 32 /127  There were no ALX -0081 treatment -related effects on electrocardiogram (ECG) and organ 
weight. No changes in ophthalmological and auditory parameters were noted in both guinea 
pig and cynomolgus monkey. In summary, these findings confirms that even at high doses (and exposures) effects on FVIII levels are within expected ranges, the clinical observations in the nonclinical species correlate with the minor findings in clinical trials so far and that continuous treatment with high doses of ALX -[ADDRESS_557644] level (NOAEL) was higher than 20 mg/kg/day since no adverse effects were 
observed.  
 Local tolerance has been studied in rabbits,  by [CONTACT_439912] i.v., s.c., i.m., intra-
arterial (i.a.) and paravenous routes in doses up to 1.2 mg/kg b.w. administered in 0.5 mL/kg. No test item -related alterations were observed.  
 Immunogenicity was evaluated during toxicology studies in guinea pig and cynomolgus monkey. In general, ADA could be detected in a limited subset of animals after i.v or s.c. 
single or multiple dose (MD) administration in both species, which did however not 
compromise the exposure. Moreover, PD  markers were not affected by [CONTACT_439913], indicating indirectly that these antibodies were not neutralising the activity of ALX -0081.  
 In conclusion, ALX- 0081 has been well tolerated in guinea pig and cynomolgus monkey used 
as relevant toxicology animal species as a consequence of (i) high target specificity (ii) a mode of action specific for pathological conditions and (iii) a unique self -regulating PK profile 
which leads to rapid clearance of excess drug.  
 
2.4 Clinical Experience  
 Currently, Ablynx is developi[INVESTIGATOR_84065] -vWF Nanobody for the treatment of TTP. For full details 
on the clinical development of ALX -0081, see the Investigator’s Brochure. 
Completed and ongoing clinical trials with anti -vWF Nanobody are listed in Table 2 . 
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 33 /127  Table 2: Overview and current status of clinical trials with anti -vWF Nanobody.  
Study number  
(EudraCT N°)  Study title  Phase  Status  
Clinical trials supporting ACS indication  
ALX-0081- 01/06  
(2006- 006502- 28)8 A Phase I, double blind, randomized, placebo-
controlled, parall el group study in healthy male 
volunteers to investigate the safety, tolerability 
and pharmacokinetics of the Nanobody 
ALX-0081 administered intravenously as 
single ascending doses  Ia Completed  
ALX-0081 -1.2/08  
(2007- 007263- 24)9  
 A Phase I double blind, placebo controlled 
study of ALX -0081 multiple dose 
administrations in stable angina patients 
undergoing PCI  Ib Completed  
 
ALX-0081 -2.1/09 
(2009- 012206- 39) A Phase II randomized, open label cli nical trial 
in high risk percutaneous coronary 
intervention (PCI) patients receiving standard 
antithrombotic treatment plus either ALX -0081 
or GPI[INVESTIGATOR_97086]/IIIa inhibitor (ReoPro®) over a period 
of 24 hours  IIa Completed (final data 
analysis and reporting ongoing)  
Clinical trial supporting TTP indication  
ALX-0681 -1.1/08  
(2008- 006624- 60)[ADDRESS_557645] received one or more doses of anti -vWF Nanobody is 
provided in Table 3 . 
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 34 /127  Table 3: Exte nt of exposure for anti- vWF Nanobody.  
  Dose  Duration 
(Days)  No. Subjects  
SUBCUTANEOUS  
Healthy Volunteers     
ALX-0681- 1.1/08  2 mg  1 3 
Adults – male and female 4 mg  1 3 
  8 mg  1 3 
  10 mg 1 3 
  16 mg 1 3 
  10 mg 7 6 
  10 mg 14 6 
Total  27 
INTRAVEN OUS 
Healthy Volunteers     
ALX-0081- 01/06  0.5 mg x 1 infusion (1h)  1 3 
Adults - male  1 mg x 1 infusion (1h)  1 3 
  2 mg x 1 infusion (1h)  1 3 
  4 mg x 1 infusion (1h)  1 3 
  8 mg x 1 infusion (1h)  1 3 
  12 mg x 1 infusion (1h)  1 6 
Total  21 
Stable Ang ina Patients 
undergoing PCI     
ALX-0081- 1.2/08  2 mg x 1 infusion (1h)  1 3 
Adults - male and female 4 mg x 1 infusion (1h)  1 3 
  6 mg x 1 infusion (1h)  1 3 
  9 mg x 1 infusion (1h)  1 3 
  6+4+4+4 mg q6h infusions (1h)  1 6 
  6+4+4+4 mg q6h bolus  1 20 
Total 38 
High risk PCI patients     
ALX-0081- 2.1/09  6+4+4+4 mg q6h bolus  1 181 
Adults - male and female    
TOTAL  267 
 
In the following sections, a summary of the setup and results for the studies listed in Table 2 
is provided.  
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 35 /[ADDRESS_557646] been approved. The Phase Ia trial in healthy male volunteers has been completed successfully, as well as the SD and MD stages of the Phase Ib trial in stable angina patients undergoing elective PCI. An open- label extension (OLE) of the latter trial to 
evaluate administration of ALX -0081 by i.v. bolus injection compared to i.v. infusion has 
completed the treatment phase. Finally, a Phase II trial in high risk PCI patients, comparing ALX-0081 and ReoPro
® was initiated in July 2009. 
 
The Phase Ia trial was designed to assess the safety, tolerability and PK of ALX -[ADDRESS_557647] dose of study medication was i.v. 500 µg ALX -0081 or 
placebo (dose level 1) followed by 2- fold, [ADDRESS_557648] dose in 
dose levels 2- 6, respectively.  
 
The subsequent Phase Ib study was designed to determine the maximum tolerated dose (MTD) and/or biologically effective dose (BED) and the Phase II recommended dose of ALX-0081 in ACS patients. In addition, this study aimed to determine the safety and 
tolerability of escalating doses of ALX -0081 in patients undergoing PCI and to document the 
biological and clinical response to therapy. In Stage A of the study, single ascending doses (2, 4, 6 and 9  mg) of ALX -0081 (n = 3 per dose level) or placebo (n = 1 per dose level) were 
administered as a 1h i.v. infusion. In the second stage of the trial (Stage B), multiple dosing was evaluated and subjects received an initial dose of 6 mg, followed by 3 subsequent doses of 4 mg every 6 hours (n = 6 ALX -0081 and n = 2 placebo). Route of administration was also 
i.v. infusion . Following Stage B, an open label extension was initiated with 22 subjects (Stage 
C) (n = 20 ALX -0081 and n = 2 placebo) in order to determine the optimal i.v. route of 
administration for ALX -0081 in man (bolus injections or 1 hour infusions).  
 
The conclusions of both trials can be summarised as follows:  
• Single and multiple i.v. administrations of ALX -0081 are safe and well tolerated  
• The BED (providing a complete inhibition of vWF- mediated platelet aggregation 
for > 24 hours) and Phase II recommended dose is a SD of 6 mg, followed by 3 
subsequent doses of 4 mg every 6 hours, given as i.v. bolus injections  
• RICO can be used as a reliable biomarker for the PD effect of ALX -0081, i.e. inhibition 
of vWF -mediated platelet aggregation Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 36 /127  • In subjects receiving the BED, mean RIPA values below 10% were maintained for a 
maximum of 24 hours and clinically relevant RICO inhibition was maintained for a 
maximum of 30  hours  
• Non-linear PK properties were determined  
• Half-life values were similar after single and repeated dosing. ALX- [ADDRESS_557649] reached a steady state  
• There were no apparent clinical differences between the treatment groups with  
regards to the number of subjects with (S)AEs, nor with regards to the AE profile 
• The only adverse drug reactions clearly attributable to ALX -0081 administration were 
alterations of the coagulation parameters. Mild, transient and non- dose dependent 
decreases in FVIII and vWF were observed, but were not considered clinically  
relevant. A summary of the safety findings of both trials is provided in the following table  
Table 4: Safety summary of Phase I trials with i.v. administration of anti -vWF Nanobody.  
Trial  Group # Subj  vWF Ag  
decrease  FVIII  
decrease  Bleeding  
signs  IPR AEs SAEs  
Phase Ia  Placebo  19 0 0 0 1 (5%)  1 (5%)  0 
 ALX-008
1 21 8 (38%)  6 (29%)  0 3 
(14%)  5 (24%)  0 
Phase Ib  Placebo  6 + 
2OLE  0 2 (25%)  2 (25%)  3 
(38%)  8 
(100%)  2 
(25%)  
 ALX-008
1 18 + 
20OLE  38 
(100%)  38 
(100%)  3 (8%)  21 
(55%)  33 
(87%)  7 
(18%)  
 
• No immunogenic responses were detected up to 30 days after administration of 
ALX-0081  
 
Based on the results of the Phase I studies, a Phase II, randomized, open- label clinical trial 
was initiated in high risk acute coronary syndrome (ACS) patients undergoing PCI. The objective of the study was to compare the safety, and more specifically bleeding risk, of ALX-0081 versus the GPI[INVESTIGATOR_97086]/IIIa inhibitor ReoPro
® (abciximab) in 364 high risk PCI patients 
(181 and 183 in the ALX -0081 and abciximab treatment groups respectively), and to assess 
tolerability, as well as biological and clinical effectiveness.  
 The Phase II study has just been completed, and reporting is currently ongoing. Based on the available results, there were no significant safety concerns raised for treatment with ALX-0081 in this study, and the results seen were as would be expected for this patient Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 37 /127  population of high risk PCI patients. For additional details and interim results of this study, 
please refer to the Investigator’s Brochure.  
 
2.4.2  Clinical Trial Supporting TTP Indication: Phase I Study in Healthy 
Volunteers  
 The goal of this Phase I trial (ALX -0681- 1.1/08) in healthy volunteers was to determine the 
MTD or BED a nd the Phase II dosing and scheduling of ALX -0081, in order to support the 
further clinical development of ALX -0081 in TTP patients.  
In total, 36 healthy volunteers were included in this randomised, placebo- controlled study to 
evaluate the safety of single ascending doses and multiple doses of ALX-0081 administered 
s.c. ( Table 5).  
 
Table 5: Dosing schedule for Phase I trial with ALX- 0081 by s.c. administration.  
Cohort Dose (mg) Number of dai ly 
doses  Subjects receiving  
ALX-0081  Subjects receiving 
placebo  
SD     
Cohort 1  2 1 3 1 
Cohort 2  4 1 3 1 
Cohort 3  8 1 3 1 
Cohort 4  16 1 3 1 
Cohort 5  10 1 3 1 
MD     
Cohort 6  10 7 6 2 
Cohort 7  10 14 6 2 
 
PK results  
After s.c. administration, ALX -0081 plasma concentrations increased in all dose groups with 
a mean t max ranging from 4 to 10 h postdose. Mean peak plasma concentrations ( Cmax) were 
219.7, 385.7, 443.7, 528.0 and 611.0 ng/mL for the 2, 4, 8, [ADDRESS_557650] and AUC inf. 
  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 38 /127  PD results  
Inhibition of the biomarker RICO was observed in all doses groups ranging from 70% 
inhibition in the 2 mg dosing group to approximately 90% inhibition in the other SD groups. 
Reversal towards basal levels took place after approximately [ADDRESS_557651] dosing. A rapid and sustained inhibition of approximately 90% was observed after dosing in both MD groups. Values returned to basal levels at day 15 and day 22 after 7 days and 14 days MD respectively. In all dose groups of the SD part of the study complete RICO inhibition (defined as values < 20%) was observed from 4 -18 h (2 mg), 12- 18 h (4 mg), 4- 24 h (8 mg), 4- 36 h 
(10 mg) and 4- 48 h (16mg) after dosing. In both groups of the MD part of the study RICO 
was completely inhibited from 2- 168 h after dosing, i.e. from day 1- 8 (7 day) and  from 2 -360 
h after dosing, i.e. day 1- 16 (14 day). A summary of the main PD findings is provided in 
Table 6 . 
 
Table 6: Summary of main PD results (number (%) of subjects with event).  
Dose l evel Subjects 
(n) RICO < 20%  vWF  
< 50%  FVIII  
< 50%  Subjects (%)  Start (h)*  Stop (h)*  
SD       
2 mg  3 2 (67)  2-4 12-18 3 (100)  0 (0) 
4 mg  3 2 (67)  4-6 18-36 1 (33)  1 (33)  
8 mg  3 3 (100)  2-4 18-48 3 (100)  3 (100)  
16 mg  3 3 (100)  1-4 48 0 (0) 2 (67) 
10 mg  3 3 (100)  2-6 24-36 3 (100)  3 (100)  
Placebo  5 0 (0) NA NA 0 (0) 0 (0) 
MD       
10 mg (7d)  6 6 (100)  2-4 168-192 5 (83)  3 (50)  
Placebo (7d)  2 0 (0) NA NA 0 (0) 0 (0) 
10 mg (14d)  6 6 (100)  2-4 336-360 5 (83)  5 (83)  
Placebo (14d)  2 0 (0) NA NA 0 (0) 0 (0) 
* Time relative to first administration 
NA: not applicable  
 
Safety  
Overall the study drug ALX -[ADDRESS_557652] reported 1 related AE. In the MD 7 days part of the study, a total of 5/6 subjects (83%) reported 13 related AEs in the verum group compared 
to 2/2 subjects (100%) reporting 2 related AEs in the placebo group. In the MD 14 days part of the study a total of 6/6 subjects (100%) reported 46 related AEs in the verum group compared to 1/2 subjects (50%) reporting 1 related AE in the placebo group. A dose Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 39 /127  dependency was not observed, but more related AEs were shown after longer treatment in 
the MD group of the study, including an increase of the number of bruises and bleedings, all 
being of mild intensity. All injection and puncture site reactions were of mild intensity and therefore clinically not relevant. The SD part of the study showed no dose relationship regarding incidence and severity of AEs. Since there was only one active dose level used in the MD part of the study no conclusions can be drawn concerning dose dependency of AEs. Main safety results are summarised in Table 7.  
Table 7: Summary of main safety results (number (%) of subjects with event, both rel ated 
and unrelated events).  
Dose level  Subjects 
(n) AE SAE Bleeding  Haematoma 
at injection 
site Haematoma 
at blood 
sampling site  Other 
haematoma  
SD        
2 mg  3 2 (67)  0 (0) 1 (33)  0 (0) 1 (33)  0 (0) 
4 mg  3 2 (67)  0 (0) 1 (33)  0 (0) 0 (0) 0 (0) 
8 mg  3 3 (100)  0 (0) 0 (0) 0 (0) 1 (33)  0 (0) 
16 mg 3 3 (100)  0 (0) 0 (0) 0 (0) 0 (0) 1 (33)  
10 mg 3 1 (33)  0 (0) 0 (0) 0 (0) 1 (33)  0 (0) 
Placebo  5 3 (60)  0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
MD        
10 mg (7d)  6 6 (100)  1 (17)*  5 (83)  1 (17)  0 (0) 3 (50)  
Placebo (7d)  2 2 (100)  0 (0) 1 (50)  0 (0) 1 (50)  0 (0) 
10 mg (14d)  6 6 (100)  0 (0) 5 (83)  5 (83)  4 (67)  5 (83)  
Placebo (14d)  2 2 (100)  0 (0) 1 (50)  0 (0) 0 (0) 0 (0) 
* unrelated SAE, meniscus lesion of the knee  
 
Immunogenicity  
Anti-ALX- 0081 antibody response was measured on day 1 (predose), day 7, day [ADDRESS_557653] had an initial positive response at follow -up. However, no samples were 
confirmed as showing treatment emergent positive responses, indicating the absence of an immunogenic response to ALX -0081.  
 
Overall conclusion 
In summary it can be concluded that s.c. administration of ALX -0081 as a SD or 
administered as daily injection for up to 14 days was well tolerated and no difference could be detected regarding the number of subjects with AEs and their severity between ALX-0081 - and placebo- treated subjects. All injection and puncture site reactions were of 
mild intensity and were classified as clinically not relevant. The PD parameters for Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 40 /[ADDRESS_557654] and reversible decrease compared to pre- dose 
values. None of the observed decreases in FVIII were recorded as abnormal/clinically 
significant PD assessments or as AEs. Values normalised between [ADDRESS_557655] 
dosing, depending on the dose. The biomarker RICO was completely inhibited in all subjects 
from a SD of 10 mg onwards for 24h, indicating biological efficacy. The biomarker was continuously suppressed below complete inhibition levels throughout the entire multiple dosing part, indicating continuous biological efficacy for > 14 days. Immunogenicity assay results indicated the absence of an immunogenic response to repeated daily administrations of s.c. ALX -0081 for up to 14 days as analysed for a minimum 45 days following completion 
of treatment.  
 
2.5 Safety/Risk Profile  
 The risk assessment for the application of ALX -[ADDRESS_557656] been highly predictive for the human situation in terms of PK/PD and safety.  
 
2.5.1  Potential Risks  
 
Toxicity  
Subchronic toxicity studies of ALX -0081 (13 weeks) have been performed in cynomolgus 
monkeys and guinea pi[INVESTIGATOR_14107]. In both studies the NOAEL proved to be above 4x10 mg 
ALX-0081/kg body weight, the maximum allowable volume of administrations per day for a 
guinea pig or cynomolgus monkey study. The biomarker RICO was inhibited during the toxicity studies, thereby [CONTACT_439914] -0081. 
Comparing the results obtained with the 13 weeks cynomolgus monkey toxicity study with a fixed daily dose of 10 mg in humans, revealed a Ratio
AUC24 of 82, demonstrating the 
presence of wide therapeutic window. Using PK modeling a predicted human exposure of 
10.3 µg.h/mL (AUC 24h) following a possible bid 10 mg administration (20 mg/subject/day) can 
be compared to exposure reached in toxicity studies with a resulting ratio of 54 for cynomolgus monkey.
 Due to the conservative correction factor applied in the exposure 
margin calculations of guinea pi[INVESTIGATOR_439858], a 10- fold systemic exposure margin could not be demonstrated in the guinea Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 41 /[ADDRESS_557657] relevant safety concern for ALX -0081. In this context ALX -0081 
was investigated in a preclinical surgical bleeding model.
11 In this study, surgical blood loss in 
animals receiving ALX -0081 was comparable to blood loss in Heparin® treated animals, and 
2- and 4 -fold less than in Plavix® and ReoPro® treated animals, respectively. This indicates 
that ALX -0081 may be safer than Plavix® and ReoPro® in terms of bleeding risk. The 
ALX-[ADDRESS_557658] toxicity studies in cynomolgus monkey, anti -FVIII antibodies 
(AFA) were detected in 4 male animals with no associated clinical signs, and in one animal 
with associated haemolytic anaemia, signs of inflammation and extremely low FVIII:C 
activity. More details are included in Section 4.3 of the Investigator’s Brochure.  
 A good understanding of the biology of vWF and the clinical presentation of patients with deficiency of vWF helps to understand the observations seen in the conducted preclinical and clinical studies and to assess the risk for bleeding appropriately. It is well known that most patients suffering from a deficiency of vWF (vWD) have mild- to-moderate quantitative 
deficiencies of vWF and FVIII, which are co- ordinately reduced to 5 to 30 percent of normal 
plasma levels (5 to 30 IU/dL).
12 This reduction is not associated with spontaneous bleeding 
but with bleeding after surgery (which is typi[INVESTIGATOR_439859]) and mucosal tract haemorrhages such as epi[INVESTIGATOR_439860] (which are typi[INVESTIGATOR_439861] ). 
It should be taken into account that these patients have a chronic, i.e. life- long, impairment of 
vWF and their vWF levels always stay far below 30 IU/dL. These patients don’t receive 
regular prophylaxis, because their bleeding tendency is less severe. Only in patients with chronic and complete absence of vWF or levels below 5- 10 IU/dL is a prophylaxis with vWF 
and FVIII indicated.  
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 42 /127  Since ALX -0081 interacts with the A1 domain of vWF, RICO is inhibited also during the 
toxicity studies. In addition, statistical significant drops in FVIII and vWF:Ag levels were 
observed in cynomolgus monkeys. In guinea pi[INVESTIGATOR_14107], the observed effects on FVIII were less pronounced. Although drops for FVIII were observed in both species, sufficient FVIII remained available to ensure proper coagulation (see also 2.3.3). No signs of bleeding, other than bruising at the injection sites were observed in the guinea pig study. In the cynomolgus monkeys study, slightly increased bleeding at injection sites were recorded in one male (4 mg/kg/day) and two females (4 and 40 mg/kg/day). Mucosal bleedings (1 exaggerated 
menstrual bleeding and 1 nose bleed) were observed in the same females. Importantly, although systemic exposure reached levels up to 80- fold higher than what can be expected 
in men during the Phase II trial, no signs of internal bleeding were observed. The observed 
clinical effects in cynomolgus monkeys are in line with the clinical presentation of patients with a mild to moderate vWD.  
From the safety data collected from the Phase I studies in healthy volunteers and patients with stable angina, a single i.v. administration of 0.[ADDRESS_557659] and 
reversible decrease of FVIII and vWF.  The average decrease of vWF levels ranged from 
approximately 50% decrease in low dose groups to 70% decrease, compared to pre- dose 
level, in the high dose groups. For FVIII, a rapid average decrease can be found in all doses groups ranging from 30%, compared to pre- dose level, in the 2 mg dosing group to 50- 65% 
in the other SD groups. Reversal takes place after approximately 72 h after dosing. A sustained decrease of approximately 50% can be found after dosing in both MD groups. Levels are back to basal levels after approximately [ADDRESS_557660] dosing in the MD groups. None of the observed decreases in FVIII were recorded as abnormal/clinically significant PD assessments or as AEs.  
 In summary, in all healthy subjects and patients with stable angina, the treatment with ALX-0081 resulted in a rapid and reversible reduction of vWF and FVIII levels, but this 
reduction never reached the levels indicating spontaneous bleeding for patients with mild or Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 43 /[ADDRESS_557661] of care 
treatment. Other TTP patients carry an underlying disease (e.g. human immunodeficiency 
virus (HIV) or cancer) associated with a depressed immune status. In both groups of TTP patients the probability for development of ADA is anticipated to be reduced.  
 
2.5.[ADDRESS_557662] three decades, the condition still carries a significant risk of mortality and morbidity. The mortality rate of acute bouts in acute idiopathic TTP, in patients managed 
with the current therapi[INVESTIGATOR_439862] 10% to 30%.
1,13,14 In the case of secondary 
TTP, PE and transfusion are recognised to be less effective and the mortality rate is 
considerably higher. In the cases when the disease is secondary to pregnancy, in which PE is regarded as reasonably effective the mortality rate of an acute bout of TTP is approximately 25%, rising to over 40% in cases with concurrent pre- eclampsia.
15 However, in 
cases secondary to, for example, underlying malignancies or bone marrow transplant the mortality rate remains at 40% to 60% despi[INVESTIGATOR_439863].
14,16,17 
  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 44 /[ADDRESS_557663] been proposed to underlie the condition. The inhibition of ULvWF- mediated platelet 
aggregation represents a rational approach to treatment that may prove to be of value in the management of all subtypes of TTP. Given the continuing significant level of mortality from TTP and the observed complications of  PE and transfusion, there is a clear need for the 
development of such additional therapeutic approaches to supplement, or potentially reduce 
the need for, these methods of treatment. On the basis of the available information, 
ALX-0081 may offer such an additional option to further improve the management of TTP.  
 
Potential benefit of ALX -0081 in TTP: efficacy  
The current therapy of TTP with PE and transfusion provides replacement ADAMTS13 and 
removes antibodies against the enzyme, thus progressively leading to a normalisation of ULvWF processing. However, this treatment requires multiple exchanges and transfusions over many days, during which time there is no direct pharmacological targeting of the active process of ULvWF -mediated platelet aggregation. ALX -[ADDRESS_557664] on ADAMTS13 function and, therefore, would not be anticipated to interfere with the enzyme replaced by [CONTACT_439915].  In a modified 
Folt’s model in baboons, which represents a relevant model for ACS, ALX -[ADDRESS_557665] with a lower degree of bleeding compared with other antithrombotic agents. In an initial Phase I study, ALX -0081 has been 
demonstrated to inhibit ristocetin induced platelet aggregation (a vWF -mediated process) in 
the blood of healthy volunteers. On the basis of these findings, it can be reasonably anticipated that ALX -[ADDRESS_557666] recovered from an acute bout of TTP to prevent relapses 
of the disease. A reduced frequency of acute bouts of TTP would represent a significant Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 45 /127  benefit, with a potential for a reduction in the mortality and morbidity associated with TTP and 
a further reduction in the need for PE and transfusions over a patient’s lifetime.  
 
Potent ial benefit of ALX -0081 in TTP: quantification of major contribution to patient 
care 
For acquired TTP, the hypothesis of the proposed Phase II trial is to demonstrate a decrease 
of 44% in the time -to-response, objectivated by a recovery of platelets ≥ 150, 000/µL. Platelet 
count increase is a sign of diminished pathological platelet aggregation, as well as a better protection against bleeding. The decrease of LDH is a sign of decreased haemolysis and/or tissue ischaemia. This response must be confirmed up to 48 hours after the time -to-
response.  
 
Potential benefit of ALX -0081 in TTP: safety  
While a more rapid recovery from TTP and a potential for a reduction in exacerbations and 
relapses would be of clear clinical benefit in terms of treatment efficacy, the potential for a reduction in the duration and frequency of PE and transfusion would also provide additional benefits in terms of patient safety.  
Although PE and transfusion are currently regarded as the standard treatment in the management of TTP, the procedures carry the risk of significant complications. The PE 
procedure requires high fluid volumes and flow rates necessitating the use of central venous 
dual lumen haemodialysis catheters. Complications from the procedure include haemorrhage 
from catheter ins ertion, sepsis, catheter thrombosis, pneumothorax, fluid overload, hypoxia 
and hypotension.
18-22 Anaphylactoid reactions complicate 0.25% to 0.5% of procedures.13,[ADDRESS_557667] frequent causes of transfusion-related fatalities with an incidence estimated to be 0.02% to 0.05% per plasma c ontaining 
unit
18 with a daily average of 17 plasma units, the daily risk can be calculated to a range of 
0.34% to 0.85%. Most patients with TTP require multiple PEs and transfusions. Patients with 
acute idiopathic TTP require daily treatments, and an average of approximately 16 
treatments is required to achieve remission.13 In refractory cases the frequency of treatment 
may be increased to twice- daily.13 In the case of patients with familial TTP, regular 
prophylactic plasma infusions at two to three week intervals are recommended.23 
Anaphylaxis and TRALI thus represent clear risks to patients with TTP whose treatment requires such a frequency and regularity of PEs and transfusions. While it is thought that this 
risk may be lower if solvent/detergent (S/D) treated plasma is used instead of fresh frozen 
plasma, the use of large volumes of S/D plasma may be associated with an increased risk of 
venous thromboembolism.
13,18 Overall, it is estimated that approximately 30% to 40% Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 46 /127  of patients will experience adverse effects from PE and transfusion, and the mortality rate 
from the procedure is of the order of 2% to 3%.2,[ADDRESS_557668] in the treatment of patients with TTP.  
 Potential benefit of ALX -0081 in TTP: quality of life  
Following recovery from a bout of TTP, many patients describe cog nitive abnormalities for 
many years and report troublesome problems with memory, concentration, decreased energy and fatigue. Such symptoms have a negative impact on the quality of patients’ daily lives. Furthermore, this deficit in quality of life may occur in all patients who have TTP, regardless of the aetiology and severity.
[ADDRESS_557669] ALX -0081 may permit more rapid control of acute bouts of TTP when used in 
combination with PE and transfusion. This would potentially reduce the risk of organ ischaemia and a more rapid normalisation of the platelet count could also reduce the risk of haemorrhagic complications. Its use may also result in improved outcomes in poorly responsive patients, including those with secondary TTP where mortality from the disease Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 47 /[ADDRESS_557670] was observed, namely RIPA ≤ 10% in healthy 
volunteers and RICO ≤ 20% in ACS patients (see section 2.4). It is believed that all active 
ULvWF present in the blood that has not yet aggregated platelets can be inhibited from 
further platelet aggregation by [CONTACT_439916] i.v. injection of [ADDRESS_557671] ( i.e. RICO ≤ 20%) is seen for a wide range of ALX -0081 
plasma concentrations, i.e. between 100- 500 ng/mL for 7 treatment days and between 100-
350 ng/mL for [ADDRESS_557672] that the proposed doses allow for full 
target occupancy and subsequent complete inhibition of the biomarker in patients with vWF 
levels within the range of 1 to 3 fold above the previously studied levels in healthy subjects and patients suffering from ACS. This range of target occupancy (i.e. saturation of pl asma 
vWF) lies within the reported levels of plasma vWF for patients undergoing PE as treatment for TTP. 
25,26 
 The dosing scheme allows for a study drug treatment interruption based on clinically significant adverse drug reaction (i.e. bleeding events).  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 48 /127  3. OBJECTIVES 
 
Primary  
• Reduction of time- to-response, defined by [CONTACT_439896], confirmed at 48 hours after the initial reporting of this response 
 Secondary (including longer- term disease sequelae)  
• Improvement in number of subjects responding to therapy  
• Reduction in PE procedure- related items  
• Reduction of time to resolution or improvement of symptoms typi[INVESTIGATOR_439851], including blood markers  
• Reduction of number of exacerbations (defined as recurrent thrombocytopenia 
following a response and requiring a re -initiation of daily PE treatment after ≥ 1 day 
but ≤ [ADDRESS_557673] daily PE) and relapses (defined as de novo event of TTP 
that occurs later than [ADDRESS_557674] daily PE)  
• Improvement of cognitive level at steady state post acute phase  
• Improvement of clinical symptoms and organ function  
• Reduction in mortality within the PE treatment period and within the subsequent study 
drug treatment period (including tapering)  
• Reduction of concomitant treatment -related complications  
• Evaluation of safety and immunogenicity of adjunctive treatm ent with ALX -0081 
• Determination of PK and PD characteristics of ALX -0081 in patients with acquired 
TTP 
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 49 /127  4. TRIAL DESIGN 
 
4.1 Study Endpoints  
 
4.1.1  Primary Endpoint  
 
• Time -to-response, based on the following criteria:  
− Recovery of platelets ≥ 150,000/µL  
− This response must be confirmed at 48 hours after the initial reporting of 
platelet recovery equal to or above 150,000/µL by a de novo  measure of 
platelets  ≥ 150,000/µL and LDH ≤ [ADDRESS_557675] (i.e. “confirmed platelet response”)  
 
4.1.2  Secondary Endpoints  
 
All endpoints achieved within 30 day period after end of study drug treatment:  
• Number of subjects with complete remission (defined as confirmed platelet response and absence of exacerbation)  
• Number of (subjects with) exacerbations of TTP (defined as recurrent thrombocytopenia following a confirmed platelet response and requiring a re- initiation 
of daily PE treatment after ≥ 1 day but ≤ [ADDRESS_557676] daily PE) and time to 
first exacerbation of TTP  
• Number of subjects relapsing of TTP (defined as de novo event of TTP that occurs 
later than [ADDRESS_557677] daily PE)  
• Number of daily PE sessions, number of plasma units administered and number of days of daily PE  
• Resolution of non -focal neurological symptoms as defined by [CONTACT_439897], measured by a neurocognitive test battery  
• Resolution or improvement (improvement of ≥ 1 grade in the CTCAE v4.0 scale) of 
TTP-related signs and symptoms as captured on physical examination and as 
adverse events, at complete remission and at end of the study drug treatment period (including tapering) (by [CONTACT_439917] A Es) 
• Total mortality within the PE treatment period and within the subsequent study drug treatment period (including tapering)  
• Incidence of PE treatment -related AEs, such as, but not restricted to: haemorrhage 
from catheter insertion, sepsis, catheter thrombosis, pneumothorax, fluid overload, hypoxia, hypotension, anaphylactoid reactions and TRALI  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 50 /127  • Incidence and severity of ALX -0081 treatment -emergent AEs and relationship to 
study drug 
• Development of ADA ≤ [ADDRESS_557678] study drug treatment  
• PK and PD profile 
 
4.1.3  Tertiary Endpoints 
 
 
   
 
  
 
  
 
4.2 Overall Study Design  
 This is a Phase II multicentre, single -blinded, parallel design, randomised, placebo- controlled 
study. The study population is symptomatic patients with acute epi[INVESTIGATOR_439850], requiring treatment with PE.  After confirmation of eligibility to study participation, subjects will 
be randomised in a ratio of 1:1 to either receive ALX -0081 or placebo as adjunctive therapy 
to PE ( Figure 4).  Subjects will be randomised prior to the start of PE treatment. In 
exceptional cases however (due to need or ability to start PE in a time frame which does not allow all required screening and/or baseline study procedures to be performed), a subject 
may be randomised after the first, single PE  session, but prior to the start of the second PE 
session. This overall second PE session should be started within [ADDRESS_557679] PE on study. 
 
The subjects will be followed in different phases during this study (also see Figure 5 ): 
• Screening and baseline measurements after admission to hospi[INVESTIGATOR_307]  
• Treatment phase  
o Single i.v. bolus study drug administered via push injection 
o Daily PE adjunctive s.c. treatment phase  
o Post-daily PE s.c. treatment phase (including PE tapering if applicable, and 
study drug post -PE for [ADDRESS_557680] PE)  
• Follow -up phase Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013

Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 51 /[ADDRESS_557681], safety assessments and assessments of 
response/relapse, re -treatment and study medication dose modification will be assessed at 
each local site laboratory.   
 
 
Figure 4: Treatment flow chart.  
First PE on study: see section 4.2  
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 52 /127   
4.3 Overview of Treatment and Dosing Regimen for  Study Drug  
 
The primary treatment for acquired TTP is daily PE. Immunosuppressive treatment is also 
often administered. The centres will follow their respective guidelines for the treatment of TTP patients, regarding all items other than the study drug. Discontinuation of daily PE 
depends on normalisation of platelet count,  neurological status and other clinical and 
laboratory parameters. The frequency of PE is occasionally reduced (‘tapered’) rather than 
stoppi[INVESTIGATOR_439864], however this is not based on randomised clinical trial data and is not recommended per this protocol (although it is allowed if considered necessary by [CONTACT_737]).  
The study drug will be administered as adjunctive treatment at specific times relative to the PE procedures.  
The first administration is a single i.v. bolus injection, administered by a push injection. All subsequent administrations are s.c. injections. The study drug consists of 10 mg of 
ALX-0081 or placebo, once daily (except if PE is given twice daily, then study drug is 10 mg 
twice daily) as described in Section 7.2.  
 
Note that, in case of re- initiation of daily plasma exchange due to exacerbation, no i.v. bolus 
injection will be administered prior to the first new PE session; daily s.c. study drug administration will continue per protocol.  
 
4.4 Study Duration  
 The anticipated recruitment period is 30 months. The maximum total duration of individual study participation is a maximum of 15 months: a treatment phase of up to [ADDRESS_557682]  
 
An independent DSMB will monitor accruing safety data during the study (SAEs on an 
ongoing basis and ‘early safety look’ when [ADDRESS_557683] completed treatment with study drug)  and will make recommendations on 
continuation of the study as appropriate. An interim analysis for safety with formal stoppi[INVESTIGATOR_439865]: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 53 /[ADDRESS_557684] to be taken to guarantee appropriate safety follow -up of all subjects already included in the study.  
The Independent Ethics Committees (IEC) or Institutional Review Board (IRB) and the Regulatory Authorities will be informed in writing about any premature termination of the study.  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 54 /[ADDRESS_557685] AWAL OF SUBJECTS  
 
The target population for this trial includes symptomatic patients with acute epi[INVESTIGATOR_439850], requiring treatment with PE.  
 
5.1 Inclusion Criteria  
 
1. 18 years of age or older  
2. Men or women willing to accept an acceptable contraceptive regimen  
3. Patients with clinical diagnosis of TTP  
4. Necessitating PE (one, single PE  session prior to randomisation into the study is 
allowed)  
5. Subject accessible to follow -up 
6. Obtained, signed and dated informed consent  
 
5.2 Exclusion Criteria  
 
1. Platelet count greater or equal to 100,000/µL  
2. Severe active infection indicated by [CONTACT_401689] (requirement for pressors with or without positive blood cultures)  
3. Clinical evidence of enteric infection with E. coli [ADDRESS_557686] antation- associated thrombotic 
microangiopathy  
8. Known congenital TTP  
9. Active bleeding or high risk of bleeding 
10. Uncontrolled arterial hypertension  
11. Known chronic treatment with anticoagulant treatment that can not be stopped safely, including but not limited to: 
• vitamin K antagonists  
• heparin or LMWH  
• non-acetyl salicylic acid non- steroidal anti -inflammatory molecules  
12. Severe or life threatening clinical condition other than TTP that would impair participation in the trial  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 55 /127  13. Subjects with malignancies resulting in a life expectation of less than 3 months  
14. Subjects with known or suspected bone marrow carcinosis  
15. Subjects who cannot comply with study protocol requirements and procedures.  
16. Known hypersensitivity to the active substance or to excipi[INVESTIGATOR_65877] 
17. Severe liver impairment, corresponding to grade 3 toxicity defined by [CONTACT_439902]. For the key liver parameters, this is defined as follows:  
• bilirubin > [ADDRESS_557687] (need to differentiate isolated increase in indirect bilirubin due to haemolysis, this is not an exclusion parameter but disease related)  
• ALT/AST > [ADDRESS_557688]  
• AP > [ADDRESS_557689]  
• gamma glutamyl transpeptidase (GGT) > [ADDRESS_557690]  
18. Severe chronic renal impairment, as defined by [CONTACT_171895] < 30 mL/min 
 
5.3 Participation in concurrent clinical trials  
 The use of another investigational drug or device within 30 days prior to screening is not allowed. Participation in non- interventional/observational studies and registries during the 
study period is allowed. Participation in another clinical trial is not allowed until the end of the 
follow up period or within [ADDRESS_557691] withdrawal from the study. Subjects that already participated in the current study (ALX 0681-2.1/10) and that have either completed the study per protocol or have discontinued prematurely,  are not allowed to be re -included.  
 
5.4 Withdrawal of Subjects from Study  
 
5.4.1  Definitions  
 
A 'completed' subject is one who has completed all phases of the study, including all follow -
up visits specified.  
A ‘withdrawal’ is a subject who stops prematurely for reasons related to the study, e.g. an AE. A subject who simply wishes to withdraw from the study should also be considered a withdrawal.  
 
 
  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 56 /[ADDRESS_557692]. These reasons include, but are not limited to the following:  
• Adverse drug reaction or AE or any other reason for which,  in the opi[INVESTIGATOR_684], subject’s continued participation in the study is not in the best interest of the subject  
• Withdrawal of consent (subject must be withdrawn)  
• Subject fails to return to the site and does not respond to the attempts of the  
investigational site to contact [CONTACT_12552] (lost to follow -up) 
• Protocol violation(s), such as non -compliance with study medication or visit schedule 
or treatment with prohibited concomitant medications  
• Pregnancy (treatment with study drug, if during treatment phase, must be discontinued and subject must be withdrawn from the study)  
Relapse of TTP on study (defined as de novo event of TTP that occurs later than [ADDRESS_557693] daily PE) is not considered a reason for study withdrawal. However re- initiation  
of study drug treatment as an adjunctive treatment to PE in case of TTP relapse is not permitted.  
 Subjects discontinuing study drug administration should be encouraged to remain in the study and complete the originally scheduled follow -up visits.  
 For all subjects withdrawing from the trial for whatever reason, all data will be collected, 
documented and reported. The case report form (CRF) must be completed up to the time of withdrawal and the Premature Termination Form must be completed. Except for subj ects 
who refuse to return to the investigational site, all subjects withdrawn after at least one administration of study drug should undergo a post -study assessment.  
 In case of withdrawal from the study due to an AE, subjects should be followed by [CONTACT_439918].  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 57 /[ADDRESS_557694] will undergo the same procedures and assessments as ‘new’ subjects. 
If a subject withdraws before  allocation of a subject number: 
• The replacement will be regarded as a ‘new’ subject and therapy allocated 
accordingly.  
If a subject withdraws after allocation of a subject number: 
• The replacement will be allocated to the same randomisation as the subject to be 
replaced, but will be allocated a new subject number.  
 The new (replacement) number is attributed by [CONTACT_439919].  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 58 /127  6. STUDY DRUGS  
 
Study drugs include the anti -vWF Nanobody (ALX -0081) and the matching placebo 
administered during the course of the study.  
6.1 Formulation, Packaging and Labelling  
 
6.1.1  Study Drug Formulation 
 
ALX-0081, anti -vWF Nanobody  
ALX-0081 is a clear, colourless solution formulated as a solution for injection. It is provided in 
sterile, preservative- free, non- pyrogenic, single -use 2R glass vials with injection stoppers 
and light blue aluminum crimped caps. One vial contains 2.4 mL solution for injection. One mL solution for injection contains as active ingredient 5 mg of ALX -0081 (INN: 
caplacizumab).  
 Excipi[INVESTIGATOR_439866] (pH 7.1):  
WFI, KCl, KH
2PO 4, Na 2HPO 4x2H 2O and NaCl. Glycine (0.2 M) and polysorbate 80 (0.02%) 
are used to stabilise the protein in the solution.  
 Placebo Placebo is provided in 2R glass vials. One vial contains 2.[ADDRESS_557695] manufacturer, supply the following medication:  
• Vials co ntaining 2.4 mL solution of 5 mg/mL of ALX -0081  
• Matching placebo vials  
The study medication will be packed and dispatched in containers. The batch number and the minimal shelf -life will be given on the outer package. A batch release certificate and a 
GMP -conformity statement will be provided. Study drugs are provided as vials for injection 
and supplied to the study centre.  
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 59 /127  6.1.3  Study Drug Labelling  
 
The study drug will be labelled in accordance with applicable regulatory requirements. At the minimum, the follow ing information will be provided
: 
• Study number (ALX -0681 -2.1/10)  
• Name [CONTACT_12165]  
• Batch number and vial number  
• Volume 
• Pharmaceutical form and route of administration (respectively i.v. or s.c.)  
• Storage conditions  
• Retest or expi[INVESTIGATOR_5695] 
• “For clini cal trial use only” and “Keep out of reach and sight of children”  
 
6.2 Storage and Stability  
 ALX-0081 and placebo are delivered and stored deep frozen at –20°C (± 5°C) in the original 
outer package to be protected from light. Stability studies showed that ALX -0081 is stable at 
-20°C for at least [ADDRESS_557696] or his/her designee will 
inspect and count all study medication for completeness. Subsequently, he/she must 
immediately return the enclosed acknowledgement of receipt form, duly completed and signed (the date of receipt must be noted).  
The pharmacist or his/her designee is responsible for storage of the study medication at the study site in an appropriate lockable room at –20°C (± 5°C). The medication may not be 
exposed to direct sunlight or to direct warmth given off by [CONTACT_439920].  
 
6.[ADDRESS_557697] or his/her designee.  
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 60 /127  Study drug preparation and administration during hospi[INVESTIGATOR_439867], all study medications will be administered by [CONTACT_439921]/her supervision.  
ALX-0081 solution for injection is for single use only. Remaining ALX -0081 solution for 
injection should be discarded. Procedures for proper handling and disposal should be observed.  
 
Study drug preparation for dispension to subjects, and administration thereafter  
Vials will be thawed in a 25°C water bath or  at room temperature until all ice has visibly 
disappeared and inspected prior to dispension to subjects. Transport of study medication 
from the hospi[INVESTIGATOR_439868]’s home should be secured between 2- 8°C. The subject 
should be instructed to keep the st udy medication cooled within a refrigerator (2- 8°C) until 
use. Injections must be prepared and administered by [CONTACT_439922].  
Vials can be used during 10 days after thawing. All thawed vials and unused injections 
should be returned to the pharmacy on a weekly basis. Note that returned vials can no longer be used for administration.  
 For detailed instructions on the preparation of the solution for injection, its administration and disposal please refer to the IB.  
 
6.4 Return of Study Drug  
 Generall y, all unused study drug (medication and packaging) must be returned to the 
Sponsor on termination of the study and after a drug accountability and reconciliation check.  
Upon permission/request of the Sponsor, and if allowed by [CONTACT_439923], 
unused study drug may be destroyed on site. The destruction has to be clearly documented, and can only occur after drug accountability and reconciliation check.  
 Used study medication can be destroyed per institution policy after drug accountability has 
been checked . 
 The pharmacist or his/her designee will be responsible for the inventory of all clinical supplies, exercising accepted pharmaceutical practices. An accurate, timely record of the clinical study supply will be maintained. The original Drug Preparation Log and Drug 
Dispensing and Accountability Log are considered as source data and will be archived at the 
site. 
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 61 /127  6.5 Drug Accountability  
 
Supplies of ALX -0081 will be shipped deep frozen at -20°C (± 5°C)  to the hospi[INVESTIGATOR_439869], depending on subject accrual. The Investigator at the study site is responsible for keepi[INVESTIGATOR_439870], the dispensing to the subjects and the return of all used and unused s tudy drug.  
A Drug Preparation Log as well as a Drug Dispensing and Accountability and temperature Log must be kept current and should contain the following information:  
 
• In hospi[INVESTIGATOR_29399]:  
o Vial number  
o Subject number for whom the drug was prepared  
o Number of injections prepared  
o Date on which drug was dispensed 
o Quantity of the drug administered  
• Use at home by [CONTACT_423]:  
o Subject number to whom the drug was dispensed 
o Information on vials dispensed  
 Number of vials dispensed 
 Vial identification numbers dispensed 
 Date of thawing  
 Date of dispension  
 Vials returned by [CONTACT_423]  
o Name [CONTACT_439967] 
o Date and time of study drug administration 
o Quantity of the drug administered  
The inventory must be available for inspection by [CONTACT_439924] r. 
Generally, at study termination, all unused study medication must be returned to the Sponsor 
accompanied by [CONTACT_76764]. Upon permission/request of the Sponsor, 
and if allowed by [CONTACT_439925], unused study drug may be destroyed on site. The destruction has to be clearly documented, and can only occur after drug accountability and reconciliation check . Used study medication can be destroyed per 
institution policy after drug accountability has been checked . Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 62 /[ADDRESS_557698] medical care and treatment judged appropriate by [CONTACT_439926]. The principal treatment for 
acquired TTP is daily PE. Discontinuation of daily PE depends on normalisation of platelet 
count,  neurological status and other clinical and laboratory parameters. The frequency of PE 
is occasionally reduced (‘tapered’) rather than stoppi[INVESTIGATOR_439864], however this is not based on randomised clinical trial data and is not recommended per this protocol (although it is allowed if considered necessary by [CONTACT_737]).  
Additional treatment may include one or more of the following: adjunctive immunosuppressive treatment (e.g. corticosteroids, rituximab), antiplatelet agents (e.g. aspi[INVESTIGATOR_248]), supportive therapy with red cell transfusion or folate supplementation, treatment with vincristine or cyclosporin in case of refractory TTP.
[ADDRESS_557699] 100,000/μL has been 
reached.  
 
7.2 Treatment and Dosing Regimen for Study Drug 
 The study drug will be administered as adjunctive treatment at specific times relative to the PE procedures. The study drug consists of 10 mg of ALX -0081 or placebo, once or twice 
daily as explained below ( Table 8).  
 Subjects will receive a first i.v. bolus of 10 mg ALX -0081 or placebo via push injection within 
6h, but not later than 15 min prior to the initiation of PE  on study (i.e., the very first PE 
session, if the subject was randomised prior to the initiation of PE, or the second PE session, 
if the subject was randomised after one, single PE session; see section 4.2). This first PE  on 
study  is followed by s.c. administration of 10 mg study drug within 30 minutes after the end of 
the PE procedure.  
 
During the complete PE treatment period (including tapering and PE given fo r 
exacerbations), study drug will be administered daily via s.c. injections.  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 63 /127  • If 1 PE per day is scheduled, 10 mg of study drug will be administered within 30 
minutes after the end of the PE procedure.  
• If 2 PEs per day are scheduled, 10 mg of study drug will be administered within 30 
minutes after the end of each PE procedure. The maximum total daily dose of study drug is hence 20 mg.  
• If less than 1 PE per day is scheduled (i.e. during a tapering regimen), 10 mg of study 
drug will be administered daily. On days with a PE, study drug administration should 
be within 30 minutes after the end of the PE procedure; on days without PE, study 
drug administration should be 24 h ( ± 1 h) after previous administration  
 
Daily s.c. study drug administration of [ADDRESS_557700] PE 
(including tapering).  
 
Maximum treatment duration with study drug will be limited to [ADDRESS_557701] administration of study drug.  
 In case of exacerbation of TTP ( after ≥ 1 day but ≤ [ADDRESS_557702] daily PE ), standard 
treatment (PE) should be re- initiated and daily s.c. administration of study drug continued.
a 
The “study drug post -PE” period (for [ADDRESS_557703] PE, see Figure 5 further 
below ) will re-commence once PE is again stopped. Maximum treatment duration with study 
drug will be limited to [ADDRESS_557704] daily PE. Tapering will prolong study drug administration and 
delay the start of the “study drug post -PE” period (see Figure 5  further below). It is therefore 
possible that a relapse would occur ≥ [ADDRESS_557705] -PE. In this case, the study drug is to be 
discontinued at the restart of the PE treatment.  
 The s.c. injections will be performed on the abdomen according to a written instruction manual. At each administration, subjects will receive two s.c. injections of 1 mL ALX -0081 
solution for injection (5 mg/mL) or placebo solution at different abdominal locations. The site 
                                                
a  Note that, in case of re- initiation of daily PE due to exacerbation, no i.v. bolus injection has to be 
administered prior to the first  new PE session; daily s.c. study drug administ ration will continue per 
protocol . Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 64 /127  of the injections will be recorded and will be changed from day to day. The time of 
administration of study drug and the initials of the person performing the administration will 
be recorded in the source documents. All injections of study drug will be performed by [CONTACT_439927].  
 
7.3 Dose modification due to treatment related AE – clinically relevant 
bleeding  
 Clinically relevant bleeding is the main potential risk based on the pharmacological action of ALX-0081. It is de fined as moderate to severe (including life- threatening) bleeding requiring 
urgent medical and/or surgical intervention. In case of clinically relevant bleeding, appropriate treatment for bleeding according to standard practice should be initiated and 
treatment with study drug must be interrupted. In addition, plasma levels of vWF:Ag and FVIII 
chromogene should be determined. If FVIII < 10%, assess for anti -FVIII antibodies and if 
presence is confirmed, permanently discontinue study drug. If either or both vWF and FVIII 
are at clinically significant low levels, administration of vWF and FVIII through commercially available combination preparations, such as Haemate- P or equivalent antihaemophilic 
factor/vWF complex should be initiated and continued until the bleeding stops. Study drug should only be restarted when the bleeding has stopped and vWF > 50% and FVIII level is within normal range. The PE treatment, if applicable, should continue as clinically indicated.  
 
Dosage, method of administration and duration of treatment are summarised in Table 8. 
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 65 /127  Table 8: Dosage, method of administration and treatment duration.  
First study drug administration is 10 mg as an i.v. bolus, administered by a push injection,  15 
minutes to 6 hours prior to initiation of PE on study.* This first PE on study is followed by 
[CONTACT_6567] (s.c.) administration of 10 mg study drug.  
* As discussed in section 4.2, one PE session prior to randomisation is allowed. In such ca se, the second PE 
session will be the first PE on study.  
 
S.c. study drug administration during treatment phase with PE  
Frequency of PE  Treatment administration - daily 
1 PE/day  Administer 10 mg study drug within 30 min after end of PE  
2 PEs/day  • For su bjects receiving anti -vWF Nanobody: administer 10 mg study 
drug within 30 min after each PE  
• For subjects receiving placebo, maintain a once daily dosing regimen 
Tapering (< 1 PE/day)  Daily administration of 10 mg study drug. On days with PE: within 30 mi n 
after end of PE; on days without PE at 24 h ( ± 1 h) after previous 
administration  
 
S.c. study drug administration (in hospi[INVESTIGATOR_418906]) for [ADDRESS_557706] PE  (including 
tapering and PE given for exacerbations)*: 10 mg study drug once daily.  
*  As discussed in section 7.2, in case of exacerbation of TTP, standard treatment (PE) should be re -initiated and 
daily administration of study drug continued. The “study drug post -PE” period (for [ADDRESS_557707] PE) 
will recommence onc e PE is again stopped. Maximum treatment duration with study drug will be limited to [ADDRESS_557708] administration of study drug.  
 
If clinically relevant bleeding* occurs  
• Stop study drug administration and continue PE if clinically indicated and app licable  
• Assess vWF:Ag and Factor VIII (FVIII) levels**. If FVIII < 10%, assess for anti -FVIII antibodies and 
if presence is confirmed, permanently discontinue study drug.  
• If vWF:Ag and/or FVIII levels are at a clinically significant low level, initiate i.v. Haemate- P 50 U/kg 
(or equivalent antihaemophilic factor/vWF complex)  
• i.v. Haemate- P treatment should be discontinued when bleeding has clearly stopped and when 
vWF > 50%  
• Restart study medication at 10 mg daily when bleeding has clearly stopped and when vWF > 50% 
and FVIII levels are within normal range  
*  Clinically relevant bleeding is defined as moderate to severe (including life-threatening) bleeding requiring 
urgent  medical and/or surgical intervention.  
** FVIII chromogene or other measure of FVIII activity  
 
7.4 Prior / Concomitant Medication  
 
Upon inclusion in the study, chronic treatment with anticoagulant treatment such as vitamin K antagonists, heparin (or LMWH) and non- acetyl salicylic acid non -steroidal anti -inflammatory 
molecules should be discontinued. If recommended by [CONTACT_13144], aspi[INVESTIGATOR_439871]. Heparin can be administered according to local institutional guidelines, or in the absence of these, after a platelet count of at least 100,000/µL has been reached. Re-initiation of anticoagulant treatment is allowed whenever required to ensure the safety of the Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 66 /[ADDRESS_557709]. (Re- )initiation of anticoagulant treatment should be guided upon balancing the risk 
for thrombosis versus the risk for bleeding and should be based upon local guidelines. For 
example, LMWH can be used prophylactically in subjects at high risk for venous 
thromboembolism whenever platelet counts have partially recovered. Anticoagulant 
treatment prescribed as part of the local PE procedure is allowed.   
Concomitant medication administered specifically as part of the PE procedure and during the 
course of the PE session will be recorded separately. Other concomitant and adjunctive medication, such as methylprednisone, rituximab and other immunosuppressives will be reported in the concomitant medication other than PE -related medication.  
Medication given in response to a PE -related AE (i.e. antibiotic administration due to a 
central line infection) will be reported in the concomitant medication other than PE -related 
medication.  
Any concomitant medication taken during the study must be recorded in the CRF. Items to 
be recorded concerning concomitant medication include: dose and units of dose, modification of dose, start time and date, end time and date, administration frequency, route  
of administration, therapeutic indication.  
Desmopressin should be considered as prohibited medication.  
 
7.5 Assignment to Treatment  
 Subjects will be assigned to one of the two treatments according to a computerised randomisation schedule. When the randomisation number and treatment assignment are obtained, the randomisation number will be recorded on the CRF. This is a single blinded study. The Investigator will be informed of the treatment at the time of randomisation.  
Randomisation is performed via an interactive web- based system.  
 
7.6 Management of Overdose  
 In case of suspected or actual overdose, there is an increased risk of bleeding based on the pharmacological action of study drug. Subjects should therefore be monitored closely for 
signs and symptoms of clinically relevant bleeding, defined as moderate to severe (including 
life-threatening) bleeding requiring urgent  medical and/or surgical intervention (see Section 
7.3). In case of clinically relevant bleeding associated with (suspected) overdose, appropriate treatment for bleeding according to standard practice should be initiated and treatment with study drug must be interrupted. In addition, plasma levels of vWF:Ag and FVIII should be determined. If FVIII < 10%, assess for anti -FVIII antibodies and if presence is confirmed, 
permanently discontinue study drug. If either or both vWF and FVIII are at clinically Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 67 /127  significant low levels, administration of vWF and FVIII through commercially available 
combination preparations, such as Haemate- P or equivalent antihaemophilic factor/vWF 
complex should be initiated and continued until the bleeding stops. Treatment with study 
drug should only be restarted when the bleeding has stopped and when vWF  > 50% and 
FVIII levels are within normal range. The PE treatment, if applicable, should continue as 
clinically indicated.  
In case of (suspected) overdose with no clinically relevant bleeding observed, study drug administration may continue with the next PE or next daily dose as applicable and as per protocol.  
 
7.[ADDRESS_557710] administration of study drug.  
 
7.9 Treatment Compliance  
 Records of study drug used, dosages administered and intervals between visits are kept 
during the study. Study drug accountability is performed on an ongoing basis by [CONTACT_439928].  
The administration of the study medication will be performed by [CONTACT_91564]-Investigator or medically trained personnel and will be documented accordingly.  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 20 13 CONFIDENTIAL   Page 68 /127  8. STUDY ASSESSMENTS AN D PROCEDURES  
 
8.1 Description of Study Days and Schedules of Assessments  
 
The subjects will be followed in different phases during this study:  
• Screening and baseline measurements after admission to hospi[INVESTIGATOR_307]  
• Treatment phase  
o Single i.v. bolus study drug administered via push injection 
o Daily PE adjunctive s.c. treatment phase  
o Post-daily PE s.c. treatment phase (including PE tapering if applicable, and 
study drug post -PE for [ADDRESS_557711] PE)  
• Follow -up phase 
 Please see Figure 5  for a schematic overview of the different study phases. A general 
overview of study assessment is shown in Table 9 . 
Time intervals and follow -up window details are provided in Table 10, Table 11 and Table 13. 
  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013   CONFIDENTIAL   Page 69 /127  
 
Figure 5: Schematic overview of pre- treatment, treatment and follow -up phase.  
* Subjects will be randomised prior to the start of PE treatment. In exceptional cases however (due to need or ability to start PE in a time frame which does 
not allow all required screening and/or baseline study procedures to be performed), a subject may be randomised after the first, single PE session, but prior 
to the start of the second PE session. This overall second PE session should be started within [ADDRESS_557712] PE on study.  
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013   CONFIDENTIAL   Page 70 /127  Table 9: General schedule of study assessments.  
 Screening  Baseline  Treatment phase Follow -up 
AE and 
unsche -
duled visit  Study dr ug i.v. bolus  Daily PE 
treatment 
phase  Day [ADDRESS_557713] daily PE 
(including PE 
tapering)  
[ADDRESS_557714] PE (including tapering)- stop study drug  Day 3  Day 7  1m 2m 3m 6m 12m 
Time interval  ≤12h prior to 
first PE on 
study  and 
study drug  15min -6h 
prior to first 
PE on study  
and study 
drug see Table 11  1 day  see Table 11  ±1d ±1d ±3d ±7d ±15d ±15d ±15d as needed  
Assessment/Activity    
Treatment with study drug   X X X         
PK (central lab)   X X X X X X X     X 
RICO (central lab)   X X X X X X X     X 
ADA (central lab)  X X X X   X X X X X X 
vWF (central lab)  X X X X X X X X X X X X 
FVIII chromogene (central lab)   X X X X X X X X X X X X 
Blood type (ABO and Rh) and direct antiglobulin 
test (DAT) (local lab)  X             
Blood chemistry (local lab)  X X X X X X X X X X X X X 
Haematology (local lab)  X X X X X X X X X X X X X 
Coagulation (local lab)  X X X X X X X X X X X X X 
Urine pregnancy test (local lab)  X       X  X    
Urinalysis (local lab)  X             
HIV1/2, HBV, HCV (local lab)  X             
Cardiac marker (TnT or TnI) (local lab)   X X X X   X    X X 
BNP or NT proBNP (local l ab)  X X X X   X    X X 
Brain damage markers (NSE, Sβ100)  
(central lab)   X X X X   X    X X 
ADAMTS13 & anti -ADAMTS13 -antibodies  
(central lab)  X   X X   X    X X 
12-lead ECG   X X X X   X X X X X X 
Informed consent  X             
Inclusion/exclusion criteria  X             
Medical history and demographics  X               Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013   CONFIDENTIAL   Page 71 /[ADDRESS_557715] daily PE 
(including PE 
tapering)  
 Day 3 Day 7  1m 2m 3m 6m 12m 
Time interval  ≤12h prior to 
first PE on 
study  and 
study drug  15min -6h 
prior to first 
PE on study  
and study 
drug see Table 11  1 day  see Table 11  ±1d ±1d ±3d ±7d ±15d ±15d ±15d as needed  
Physical examination and vital signs  X X X X X X X X X X X X X 
Spent plasma retrieval    X           
Modified ITP bleeding score   X X X X   X     X 
Clinically relevant bleeding  X X X X X   X     X 
Glasgow Coma Score  X Xc X X X         
Neurocognitive battery  X X   X      X  
Recuperate nurse sheet and/ or AE diary     X X X X X X X X X 
PE detailsa   Xa Xa Xa         
Prior/concomitant medication recording other 
than PE related treatmentb Xb Xb Xb Xb Xb Xb Xb Xb Xb Xb Xb Xb Xb 
AE re cording   X X X X X X X X X X X X 
First PE on study: see section 4.2.  
a Including RBC transfusion details  
b Including concomitant medication related and simultaneous to PE. 
c If abnormal at screening 
 
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 72 /[ADDRESS_557716] PE on study (as 
detailed in section 4.2)  and study drug, all subjects will undergo a thorough examination to 
investigate their suitability for participation in the study. Inclusion and exclus ion criteria will be 
checked. A screening log should be maintained, recording the reason when subjects are screened but not included in the study. If the subject satisfies the inclusion and exclusion criteria, informed consent will be obtained prior to randomisation and additional assessments 
will be performed within [ADDRESS_557717]  PE on study  and 
study drug.  If done within 6 hours of starting study drug, the chemistry, haematology and 
coagulation assessments can be considered baseline and do not need to be repeated (see Table 10 ).  
 
The following screening procedures must be performed prior to randomisation (see Table 
10): 
• Check in/exclusion criteria 
• Demographic data (e.g. age, height, weight, body mass index (BMI), ethnic origin and 
number of years of formal education completed). The balance should have a 
precision of at least 0.5 kg. Body weight will be recorded in kg with 1 decimal. The 
BMI will be calculated from the weight and height: BMI (kg/m
2) = weight (kg) / height 
(m) x height (m).  
• Medical history  
• Prior and concomitant medication taken during the 30 days prior to the screening 
examination are to be documented. Concomitant medication from the 30 days prior to 
screening until follow -up or started during the course of the study will be recorded on 
the Concomitant Medications page of the CRF. Concomitant medications initiated, 
stopped, up- titrated or down- titrated for an AE will also be recorded on a specific 
Concomitant Medications page of the CRF. 
• Clinical assessment will include physical examination and vital signs (blood pressure and heart rate at rest, body temperature),  
• Obtain signed and dated informed consent  
• The Glasgow Coma Score will be determined using the Glasgow Coma Scale 
(original scale), which is a neurological  scale  that measures the conscious state of 
the subject. The best eye, verbal  and motor  responses will be scored according to the 
scale and the separate scores added up to obtain the final score, ranging from 3 to 15. 
• Assessment of clinically relevant bleeding Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 73 /127  • Urinalysis (local laboratory)  
• Urine pregnancy test for female subjects (Human chorionic gonadotropin (hCG) only)  
(local laboratory)  
• Blood typi[INVESTIGATOR_007] (ABO, Rh) and direct antiglobulin test (DAT) (local laboratory)  
• Blood sampling for chemistry will include the following: glucose, bilirubin (total), AP, 
AST, ALT, LDH, C -reactive protein (CRP), hCG (for women, only if urine pregnancy 
test not feasible or inconclusive), haptoglobin, rheumatoid factor, antinucleic acid, 
iron, ferritin, transferrin, creatinine, urea (blood urea nitrogen (BUN)), uric acid, protein, albumin, sodium (Na), potassium (K), calcium (Ca), magnesium (Mg) and chloride (Cl) (local laboratory) 
• Blood sampling for haematology will include the following: haemoglobin, haematocrit, 
mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), mean 
corpuscular haemoglobin concentration (MCHC), full blood count including red blood cells (RBC), white blood cells (WBC), differential, reticulocytes, optical platelet count and immature platelet fraction (local  laboratory). In case optical platelet counts are 
not available, they can be replaced by [CONTACT_439929]. If not available in the local laboratory, immature platelet fraction measurements can be omitted  
• Blood sampling for coagulation vari ables will include: fibrinogen, aPTT, PT, 
international normalised ratio (INR), vWF:Ag, FVIII chromogene, lupus anticoagulant, anticardiolipin antibodies (antiphospholipid) (local laboratory). In case FVIII chromogene is not available in the local laboratory, it can be replaced by [CONTACT_439930] (e.g. one stage clotting assay) 
• Blood sampling for viral serology (hepatitis B virus (HBV), hepatitis C virus (HCV), HIV subtype- 1 and -2 [HIV -1 and HIV -2]) (local laboratory)  
• Blood sampling for ADAMTS13 and anti-ADAMTS13 antibody titre (central 
laboratory).  
 The following procedures must be performed after randomisation, as baseline assessments (see Table 10 ): 
• Prior and concomitant medication taken during the 30 days prior to the screening examination are to be documented. Concomitant medication from the 30 days prior to 
screening until follow -up or started during the course of the study will be recorded on 
the Concomitant Medications page of the CRF. Concomitant medications initiated, 
stopped, up- titrated or down- titrated for an AE will also be recorded on a specific 
Concomitant Medications page of the CRF. Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 74 /127  • Clinical assessment will include physical examination and vital signs (blood pressure 
and heart rate at rest, body temperature),  
• AE recording 
• Glasgow Coma Score (if abnormal at screening)  
• The neurocognitive battery, only if level of consciousness and attentiveness of the subject permits and environmental factors are appropriate to support neurocognitive 
testing (e.g. , subject is able to sit upright and interact with computer touch screen; 
subjects have eyeglasses used for reading and hearing devices, if applicable; testing area is quiet and relatively free of distracting stimuli)  
• Bleeding score according to the modified ITP bleeding score  
• Assessment of clinically relevant bleeding 
• 12-lead ECG  
• Blood sampling for chemistry (local laboratory) (only if sampling for screening was done more than [ADDRESS_557718] study drug administration)
b 
• Blood sampling for haematology (local laboratory) (only if sampling for screening was 
done more than [ADDRESS_557719] study drug administration)b  
• Blood sampling for coagulation variables (local l aboratory) (only if sampling for 
screening was done more than [ADDRESS_557720] study drug 
administration)b 
• Blood sampling for markers for cardiac cell death: Troponin T (local laboratory ). In 
case Troponin T is not available in the local laboratory, it can be replaced by [CONTACT_439931] I 
• Blood sampling for markers for heart failure: BNP (brain natriuretic peptide) or N-
terminal pro brain natriuretic peptide  (NT-proBNP) (local laboratory)  
• Blood sampling for markers for brain damage: NSE (neuron specific enolase), protein 
S100 beta (Sβ100) (central laboratory)  
• Blood sampling for PK (central laboratory). This sample needs to be drawn within [ADDRESS_557721] administration of study drug 
• Blood sampling for PD assessments . This sample needs to be drawn within [ADDRESS_557722] administration of study drug. The PD assessments include RICO, vWF (vWF:Ag and vWF propeptide) and FVIII chromogene (central laboratory).  
• Blood sampling for ADA (central laboratory). This sample needs to be drawn within [ADDRESS_557723] administration of study drug 
 
                                                
b Not to be repeated if screening assessment occurred within 6 hours of starting study drug.  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 75 /127  The procedures to be performed at screening and/or baseline are also listed in Table 10. 
 
Table 10: Schedule of assessments at screening and baseline measurements.  
Assessment/Activity  Screening  
less than [ADDRESS_557724] 
PE on study  
Informed consent  X  
In/exclusion criteria  X  
Medical history and demographic data  X  
Blood typi[INVESTIGATOR_007] (ABO and Rh) and DAT (local lab)  X  
Physical examination and vital signs  X X 
Serology (HIV1/2, HBV and HCV) (local lab)  X  
Urinalysis (local lab)  X  
Urine or blood pregnancy test for female subj ects (hCG only) (local 
lab) X  
12-lead ECG   X 
Blood chemistry (local lab)a X Xa 
Haematology (local lab)a X Xa 
Coagulation variables (local lab)a X Xa 
Prior and concomitant medication other than PE related treatment  X X 
ADAMTS13 and anti -ADAMTS13 anti body titre (central lab)  X  
PK (central lab)b  Xb 
RICO (central lab)b  Xb 
vWF (central lab)b  Xb 
FVIII chromogene (central lab)b  Xb 
ADA (central lab)b  Xb 
Cardiac marker (TnT or TnI) (local lab)   X 
BNP or NT proBNP (local lab)   X 
Brain damage mark ers (NSE, Sβ100) (central laboratory)   X 
Modified ITP bleeding score  X 
Clinically relevant bleeding  X X 
Glasgow Coma Scorec X Xc 
Neurocognitive batteryd  Xd 
AE recording   X 
First PE on study: see section 4.2.  
a values determined at screening can be used as baseline values  to avoid additional blood sampling, if screening 
assessment occurred within 6 hours of starting study drug.  
b ≤ 1h prior to first study drug administration  
c if abnormal at screening  
d if possible  
 
Blood chemistry includes glucose, bilirubin (total), AP, AST, ALT, LDH, CRP, hCG (for women, to be performed 
as soon as possible, if urine pregnancy test is not feasible or inconclusive), haptoglobin, rheumatoid factor, 
antinucleic acid, iron, ferritin, transferrin, creatinine, urea (BUN),  uric acid, protein, albumin, Na, K, Ca, Mg and Cl.  
Haematology includes haemoglobin, haematocrit, MCV, MCH, MCHC, full blood count including RBC, WBC, differential, reticulocytes, platelet count and, if available, immature platelet fraction.  
Coagulation variables include fibrinogen, aPTT, PT, INR, vWF:Ag, FVIII (chromogene or alternative method), lupus anticoagulant, anticardiolipin antibodies (antiphospholipid).  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 76 /[ADDRESS_557725] study drug administration (i.v. bolus by a push injection) in hospi[INVESTIGATOR_307], continues with the daily s.c. study drug administration in addition to the PE sessions (including PE as part of a tapering regimen) and continues for [ADDRESS_557726] be recorded or performed:  
• Concomitant medication taken since the screening and baseline must be recorded on the Concomitant Medications page of the CRF. Concomitant medications initiated, stopped, up- titrated or down- titrated for an AE will also be recorded on a specific 
Concomitant Medications page of the CRF. This must be performed daily during daily PE period, on the first day after the daily PE period and then weekly for the subsequent time interval until the last  day of study drug administration.  
• Transfusion of RBC units will be recorded according to Section [IP_ADDRESS] . This will be 
done for each transfusion. Data will be recorded as concomitant medication.  
• PE information will be recorded according to Section [IP_ADDRESS] . This will be done for 
each and all PE sessions. This includes concomitant medication specific to the PE session.  
• Peripheral and central blood line placement and replacement for PE will be recorded 
according to Section [IP_ADDRESS] . This will be done for each blood line placement and 
replacement.  
• Clinical assessment will include physical examination and vital signs (blood pressure 
and heart rate at rest, body temperature). This must be performed daily during daily PE period, on the first day after the daily PE period and then weekly for the subsequent time interval until the last day of study drug administration.  
• AE recording will be performed daily during daily PE period, on the first day after the 
daily PE period and then weekly for the subsequent time interval until the last day of 
study drug administration. All AEs will be recorded.  
• The Glasgow Coma Score will be determined using the Glasgow Coma Scale (original scale). This score will be obtained weekly if the Glasgow coma score was abnormal at screening and as long as the subject is hospi[INVESTIGATOR_439872].  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 77 /127  • The neurocognitive battery, if NOT performed at baseline, will be administered once 
as soon as possible, i.e., when level of consciousness and attentiveness of the 
subject permits and environmental factors are appropriate to support neurocognitive testing (e.g., subject is able to sit upright and interact with computer touch screen;  
subjects have eyeglasses used for reading and hearing devices, if applicable; testing area is quiet and relatively free of distracting stimuli).  
• The bleeding score according to the modified ITP bleeding score will be performed 
daily during daily PE period, on the first day after the daily PE period and then weekly 
for the subsequent time interval until the last day of study drug administration.  
• Assessment of clinically relevant bleeding will be performed daily during daily PE 
period, on the first day after the daily PE period and then weekly for the subsequent 
time interval until the last day of study drug administration.  
• 12-lead ECG daily during the hospi[INVESTIGATOR_439873]. In 
addition, an ECG will be taken on day [ADDRESS_557727] day of study drug administration.  
 
Sampling for local laboratory : 
• Blood sampling  for chemistry will include the following: glucose, AST, ALT, LDH, 
CRP, creatinine, urea (BUN), uric acid, protein, albumin, haptoglobin, Na, K, Ca, Mg 
and Cl (local laboratory). The blood sample will be drawn daily during daily PE period, 
on the first day  after the daily PE period and then weekly until the last day of study 
drug administration. 
• Blood sampling for haematology will include the following: haemoglobin, haematocrit, MCV, MCH, MCHC, full blood count including RBC, WBC, differential, reticulocytes, optical platelet count and immature platelet fraction (local laboratory). In case optical platelet counts are not available, they can be replaced by [CONTACT_439929]. If not available in the local laboratory, immature platelet fraction 
measurements can be omitted; The blood sample will be drawn daily during daily PE 
period, on the first day after the daily PE period and then weekly until the last day of study drug administration.  
• Blood sampling for coagulation variables will include: fibrinogen, aPTT, PT, INR, vWF Ag and FVIII chromogene (local laboratory). In case FVIII chromogene is not available in the local laboratory, it can be replaced by [CONTACT_439930] (e.g. one stage clotting assay). The blood samples will be drawn on Mondays, Wednesdays, Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 78 /[ADDRESS_557728] day of study drug administration.  
• Blood sampling for markers for cardiac cell death: Troponin T (local laboratory). Daily 
during daily PE period, on the first day after the daily PE period and then weekly until 
the last day of study drug administration. In case the two initial measurements indicate that values are < ULN, all subsequent tests can be omitted. In case Troponin 
T is not  available in the local laboratory, it can be replaced by [CONTACT_439931] I.  
• Blood sampling for markers for heart failure: BNP or NT -proBNP (local laboratory). 
The blood samples will be drawn on Mondays, Wednesdays, and Fridays during daily PE period, on the first day after the daily PE period and then weekly until the last day of study drug administration. In case the two initial measurements indicate that values are <ULN, all subsequent tests can be omitted.  
 
Sampling for central laboratory:  
• Blood sampling for m arkers for brain damage: NSE, Sβ100 (central laboratory). The 
blood samples will be drawn Mondays, Wednesdays, and Fridays during daily PE period, on the first day after the daily PE period and then weekly until the last day of study drug administration.  
• Blood sampling for RICO (central laboratory). Daily during daily PE period (pre- PE), 
on the first day after the daily PE period and then weekly until the last day of study drug administration. 
• Blood sampling for PK, vWF and FVIII assessments (all central laboratory) need to be 
taken at the following time points or time intervals:  
o During daily PE period:  
 3 samples on day 1: at 5- [ADDRESS_557729] - i.v. 
administration of study drug, but prior to the second PE  
 4 samples on day 2: after PE, but prior to s.c. study drug, and at [ADDRESS_557730] -study drug, but prior to the next PE  
 [ADDRESS_557731] day of PE: after PE, but prior to s.c. study drug 
o On first day after the daily PE period:  
 4 samples: prior to study drug and at 1- [ADDRESS_557732] -study 
drug, but prior to next administration of study drug or before next PE 
(in case of tapering)  
o Subsequent time interval until the last day of study drug administration:  
 2 samples once- weekly: prior to study drug administration (but aft er 
PE, in case of tapering) and 4- [ADDRESS_557733] -study drug. Of note, for each 
day that a follow -up at the investigational site is planned, the Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 79 /127  administration of 10 mg study drug will be performed during the follow -
up visit in the investigational site. 
• Blood samples for ADA (central lab) need to be taken on day 14, and then weekly 
until the last day of study drug administration. 
• Blood sampling for ADAMTS13 and anti -ADAMTS13 antibody titre (central 
laboratory). This blood sampling needs to be performed on the first day after the daily 
PE period and [ADDRESS_557734] day of PE (including tapering) and at [ADDRESS_557735] day of PE (including tapering); the [ADDRESS_557736] PE 
(including tapering) sampling may be done at the weekly visit, even if not exactly 1 or 
3 weeks.  
• Retrieval of [ADDRESS_557737] PE procedure  on study. This will be divided in aliquots of 5 mL each for storage 
at -70°C. The retrieved spent plasma, obtained from the first plasma exchange  on 
study,  and the first spent bag will be used for following purposes.   
o As matrix for development and validation of ADA, biomarker assays that will be used in TITAN trial.  
o For further characterisation of possible immunogenicity findi ngs. 
o For additional measurement of vWF and ALX -0081 concentrations under R&D 
conditions and subsequent PK/PD modelling to assess extent of removal of these components upon plasma exchange.  
 
• Recuperate nurse sheet and/or  AE diary at each post discharge visi t. 
 An overview of assessments performed during the treatment phase of this trial is provided in Table 11 . 
 
Assessments scheduled in case of TTP exacerbation  
In case of TTP exacerbation, defined as recurrent thrombocytopenia following a response 
and requiring a re- initiation of daily PE treatment after ≥ 1 day but ≤ [ADDRESS_557738] 
daily PE, the assessments scheduled for “Day [ADDRESS_557739] daily PE” are not performed after 
completion of the exacerbation treatment, instead, the “post -daily PE (including tapering)” 
assessments are continued. A dedicated schedule of assessments is provided in Table 12. 
 
Assessments scheduled in case of TTP relapse 
Assessments scheduled in case of TTP relapse are discussed in section 8.1.3 ( Table 14 ). Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 80 /127  Table 11: Schedule of assessments during treatment phase.  
Assessment/  
Activity  Daily PE treatment phase  Day [ADDRESS_557740] daily PE  
(including PE tapering) 
Treatment with study 
drug Once daily or twice  daily  
(only if twice daily PE)a once daily  once daily ± 2 hours  
Concomitant 
medication recording 
other than PE- related 
treatment  all all weekly ± 2 days  
PE detailsb all NA NA or all in case of tapering 
Patient review/clinical assessment, including vit al signs  daily yes weekly ± 2 days  
AE recording  daily (all)  yes weekly ± 2 days (all)  
Glasgow Coma 
Score  weekly if abnormal at screening  if abnormal at screening  weekly if abnormal at screening and if 
subject hospi[INVESTIGATOR_439874], A SAPc no no 
Modified ITP bleeding 
score  daily yes weekly ± 2 days  
Clinically relevant 
bleeding  daily yes weekly ± [ADDRESS_557741] -study drug  yes weekly ± 2 days  
Blood chemistry 
(local lab ) daily pre- PE yes weekly ± 2 days  
Haematology  
(local lab)  daily pre- PE yes weekly ± 2 days  
Coagulation variables 
(local lab)  Mon, Wed, Fridays  yes weekly ± 2 days  
Cardiac marker (TnT 
or TnI) (local lab)  daily pre- PE  
if value > ULN in baseline or at da y 1 if value > ULN in baseline or at day 1  weekly ± 2 days  
if value > ULN in baseline or at day 1  
BNP or NT proBNP  
(local lab)   Mon, Wed, Fridays pre -PE 
if value > ULN in baseline or at day 1  if value > ULN in baseline or at day 1  weekly ± 2 days  
if valu e > ULN in baseline or at day 1  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 81 /127  Assessment/  
Activity  Daily PE treatment phase  Day [ADDRESS_557742] daily PE  
(including PE tapering) 
Brain damage 
markers (NSE, 
Sβ100) (central lab)  Mon, Wed, Fridays pre- PE yes weekly ± 2 days  
PK 
(central lab)  • 3 samples on day 1:  at 5-[ADDRESS_557743]-i.v. administration, but prior to second PE;  
• 4 samples on day 2: after PE, but prior to stud y 
drug, and at 1- [ADDRESS_557744] -study 
drug, but prior to next PE;  
• [ADDRESS_557745] day of PE: after PE, but prior 
to study drug  4 samples:  
• prior to study drug  
• 1-[ADDRESS_557746] study drug  
• 6-[ADDRESS_557747] study drug  
• 18-[ADDRESS_557748] -study drug, but prior to 
next administration of study drug, or 
before next PE (in case of tapering)  2 samples weekly:  
• prior to study drug, but after PE (in case of tapering)  
• 4-[ADDRESS_557749] -study drug  
RICO (central lab)  daily pre- PE yes weekly ± 2 days  
(pre-PE in case of tapering)  
vWF (central lab)  coupled to PK above  coupled to PK above  coupled to PK above  
FVIII chromogene 
(central lab)  coupled to PK above  coupled to PK above  coupled to PK above  
ADA (central lab)  only on day 14 (when at least 14 days of PE 
would be needed)   only o n Day 14 (if not performed 
previously) . weekly until the last day of study drug 
administration  
ADAMTS13 and anti -
ADAMTS13 antibody 
titre (central lab)  no yes [ADDRESS_557750] spent bag  no no 
Recuperate nurse 
sheet and/or AE diary  NA NA Post-hospi[INVESTIGATOR_2345]:  
weekly ± [ADDRESS_557751] PE on study: see section 4.2  
a Once or twice daily as detailed in the Treatment and Dosing Regimen for study drug Section 7.2 (Table 8). 
b Including concomitant medication related and simultaneous to PE procedure.  
c As soon as level of consciousness and attentiveness of the subject permits and environmental factors are appropriate to support neurocognitive testing  
d Post- discharge bleeding and any other AEs will be recorded daily by [CONTACT_439932]. The medically trained person will be instructed 
to contact [CONTACT_439933]  
e The 1-week and 3-weeks after the last day of PE  (including tapering)  sampling may be done at the weekly visit, even if not exactly [ADDRESS_557752], ALT, LDH, CRP, creatinine, urea (BUN), uric acid, protein, albumin, haptoglobin, Na, K, Ca, Mg and Cl.  
Haematology includes haemoglobin, haematocrit, MCV, MCH, MCHC, full blood count including RBC, WBC, differential, reticulocytes, optical platelet count and immature 
platelet fraction.  Coagulation variables include fibrinogen, aPTT, PT, INR, vWF:Ag and FVIII (chromogene or alternative method).  
 
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 82 /127  Table 12: Schedule of assessments during treatment phase in case of exacerbation.  
Assessment/  
Activity  Daily PE treatment phase  Post daily PE  
(including PE tapering)  
Treatment with study drug  Once daily or twice daily  
(only if twice daily PE)a once daily ± 2 hours  
Concomitant medication recording other than PE -
related treatment  all weekly ± 2 days  
PE detailsb all NA or all in case of tapering 
Patient review/clinical assessment, including vital 
signs  daily weekly ± 2 days  
AE recording  daily (all)  weekly ± 2 days (all)  
Glasgow Coma Score  weekly if abnormal at screening  weekly if a bnormal at screening and if subject 
hospi[INVESTIGATOR_439875] ± 2 days  
Clinically relevant bleeding  daily weekly ± [ADDRESS_557753] -study drug  weekly ± 2 days  
Blood chemistry (local lab)  daily pre- PE weekly ± 2 days  
Haematology  (local lab)  daily pre- PE weekly ± 2 days  
Coagulation variables (local lab)  Mon, Wed, Fridays  weekly ± 2 days  
Cardiac marker (TnT or TnI) (local lab)  daily pre-PE  
if value > ULN in baseline or at day 1  weekly ± 2 days  
if value > ULN in baseline or at day 1  
BNP or NT proBNP  (local lab)   Mon, Wed, Fridays pre- PE 
if value > ULN in baseline or at day 1  weekly ± 2 days  
if value > ULN in baseline or at day 1  
Brain damage markers (NSE, Sβ100) (central lab)  Mon, Wed, Fridays pre- PE weekly ± 2 days  
PK 
(central lab)  No 2 samples weekly:  
• prior to study drug, but after PE (in case of 
tapering)  
• 4-[ADDRESS_557754] -study drug  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 83 /127  Assessment/  
Activity  Daily PE treatment phase  Post daily PE  
(including PE tapering)  
RICO (central lab)  daily pre- PE weekly ± 2 days  
(pre-PE in case of tapering)  
vWF (central lab)  No coupled to PK above  
FVIII chromogene 
(central lab)  No coupled to PK above  
ADA (central lab)  No weekly until the last day of study drug 
administration  
ADAMTS13 and anti -ADAMTS13 antibody titre 
(central l ab) No [ADDRESS_557755] PE, 
including taperinge 
Spent plasma retrieval  No no 
Recuperate nurse sheet and/or AE diary NA Post-hospi[INVESTIGATOR_2345]:  
weekly ± 2 daysd 
a Once or twice daily as detailed in the Treatment and Dosing Regimen for study drug Section 7.2 (Table 8). 
b Including concomitant medication related and simultaneous to PE procedure.  
c As soon as level of consciousness and attentiveness  of the subject permits and environmental factors are appropriate to support neurocognitive testing  
d Post- discharge bleeding and any other AEs will be recorded daily by [CONTACT_439932]. The medically trained perso n will be instructed 
to contact [CONTACT_439933]  
e The 1-week and 3-weeks after the last day of PE (including tapering) sampling may be done at the weekly visit, even if not exactly [ADDRESS_557756], ALT, LDH, CRP, creatinine, urea (BUN), uric acid, protein, albumin, haptoglobin, Na, K, Ca, Mg and Cl.  
Haematology includes haemoglobin, haematocrit, MCV, MCH, MCHC, full blood count including RBC, WBC, differential, reticulocytes, optical platelet count and immature 
platelet fraction. Coagulation variables include fibrinogen, aPTT, PT, INR, vWF:Ag and FVIII (chromogene or alternative method).  
  
 
 
 
   Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 84 /[ADDRESS_557757] study drug administration (3 days ± 1 day, 7 days ± 1 day,1 month ± 3 
days , 2 months  ± 7 days, 3 months ± 15 days, 6 months ± 15 days, and 12 months ± 15 
days). Unless stated otherwise, a given action is to be performed at all scheduled follow -up 
visits:  
• Concomitant medication taken since the previous visit must be recorded on the Concomitant Medications page of the CRF. Concomitant medications initiated, stopped, up- titrated or down- titrated for an AE will also be recorded on a specific 
Concomitant Medications page of the CRF. Transfusion of RBC units will be recorded according to Section [IP_ADDRESS] . This will be done for each transfusion. Data will be 
recorded as c oncomitant medication 
• Clinical assessment will include physical examination and vital signs (blood pressure and heart rate at rest, body temperature)  
• AE recording 
• The neurocognitive battery will be administered at the day 3± 1 and 1 year follow -up 
visits on ly 
• Bleeding score according to the modified ITP bleeding score will be performed at the 1 month follow -up visit  
• Assessment of clinically relevant bleeding will be performed at the 1 month follow -up 
visit 
• 12-lead ECG at 1 m follow -up (± 3 days) , 2 m follow -up (± 7 days), 3 m follow -up( ± 
15 days), 6 m follow -up ( ± 15 days), and 12 m follow -up (± 15 days)  
• Urine pregnancy testing at 1 m follow -up (± 3 day) and 3 m follow -up (± 3 day) visits 
(local)  
• Blood sampling for chemistry will include the following: glucose, AST, ALT, LDH, 
CRP, creatinine, urea (BUN), uric acid, protein, albumin, haptoglobin, Na, K, Ca, Mg 
and Cl (local laboratory)   
• Blood sampling for haematology will include the following: haemoglobin, haematocrit, MCV, MCH, MCHC, full blood count including RBC, WBC, differential, reticulocytes, optical platelet count and immature platelet fraction (local laboratory). In case optical platelet counts are not available, they can be replaced by [CONTACT_439929]. If not available in the local  laboratory, immature platelet fraction 
measurements can be omitted.  
• Blood sampling for coagulation variables will include: fibrinogen, aPTT, PT, INR, vWF:Ag and FVIII chromogene (local laboratory) In case FVIII chromogene is not Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 85 /127  available in the local laboratory, it can be replaced by [CONTACT_439930] (e.g. one 
stage clotting assay)  
• Blood sampling for markers for cardiac cell death: Troponin T (local laboratory) will be 
taken at the 1 m follow -up (± 3 day) and 12 m follow -up (± 3 day) visits. In case the 
two initial measurements indicate that values are <ULN, all subsequent tests can be omitted. In case Troponin T is not available in the local laboratory, it can be replaced by [CONTACT_439931] I  
• Blood sampling for markers for heart failure: BNP or NT -proBNP ( local laboratory). 
The blood samples will be drawn at the 1 m follow- up (± 3 day) and 12 m follow -up (± 
3 day) visits. In case the two initial measurements indicate that values are <ULN, all subsequent tests can be omitted  
• Blood sampling for markers for br ain damage: NSE, Sβ100 (central laboratory). The 
blood samples will be drawn at the 1 m follow -up (± 3 day) and 12 m follow -up (± 3 
day) visits.  
• Blood sampling for PK and PD assessments (PD assessments include RICO, vWF, FVIII chromogene) (all central laboratory) need to be taken at the following time points or time intervals:  
o day 3 ± 1 day  
o day 7 ± 1 day  
o 1m follow -up ± 3 day  
In addition, blood samples for vWF  (central lab)  and for FVIII chromogene (central 
lab) need to be taken at 2m, 3m, 6m and 12m follow -up visits  
• Blood sampling for ADA needs to be taken at 1m, 2m, 3m, 6m and 12m follow -up 
visits (central lab) . 
• Blood sampling for ADAMTS13 and anti -ADAMTS13 antibody titre (central laboratory) 
needs to be taken at 1m and 12m follow -up visits  
• Recuperate the nurse sheet and/or AE diary card  
 An overview of assessments performed during the follow -up phase of this trial is provided in 
Table 13 . 
During this follow -up phase, there will be no administration of study drug.  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 86 /127  Table 13: Schedule of assessments during follow -up. 
Assessment/  
Activity  Day 3  
(± 1 d)  Day 7  
(± 1 d)  1m 
follow -
up 
(± 3 d)  2m 
follow -
up 
(± 7 d)  3m 
follow -
up 
(± 15 d)  6m 
follow -
up 
(± 15 d)  12m 
follow -
up 
(± 15 d)  AE and 
unscheduled 
visit 
Concomitant 
medication recording other than PE related 
treatment  X X X X X X X X 
Physical examination 
and vital signs  X X X X X X X X 
AE recording  X X X X X X X X 
Neurocognitive 
battery  X      X  
Modified ITP bleeding score    X 
    X 
Assessment f or 
clinically relevant 
bleeding    X     X 
12-lead ECG    X X X X X X 
Urine pregnancy test 
(local lab)    X  X    
Blood chemistry 
(local lab)  X X X X X X X X 
Haematology (local 
lab) X X X X X X X X 
Coagulation variables 
(local lab)  X X X X X X X X 
Cardi ac marker (TnT 
or TnI) (local lab)    X    X X 
BNP or NT proBNP 
(local lab)    X    X X 
Brain damage 
markers (NSE, 
Sβ100) (central lab)    X    X X 
PK (central lab)  X X X     If applicablea 
RICO (central lab)  X X X     If applicablea 
vWF (central lab)  X X X X X X X X 
FVIII chromogene 
(central lab)  X X X X X X X X 
ADA (central lab)    X X X X X X 
ADAMTS13 and anti -
ADAMTS13 antibody 
titre (central lab)    X    X X 
Recuperate AE diary  X X X X X X X If applicableb 
a i.e. during treatment phase with study drug.  
b i.e. post-hospi[INVESTIGATOR_439876], AST, ALT, LDH, CRP, creatinine, urea (BUN), uric acid, protein, albumin, 
haptoglobin, Na, K, Ca, Mg and Cl.  Haematology includes haemoglobin, haematocrit, MCV, MCH, MCHC, full 
blood count including RBC, WBC, differential, reticulocytes, platelet count and, if available, immature platelet 
fraction.  Coagulation variables include fibrinogen, aPTT, PT, INR, vWF:Ag and FVIII (chromogene or alternative 
method)  
 
 
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 87 /127  Precaution to be taken for cessation of study drug administration:  
As described in section 8.1.2, ADAMTS13 and anti-ADAMTS13  antibody titre will be 
measured from blood sampling at 1-week and 3- weeks after the last day of PE (including 
tapering). Note that the 1- week and 3- weeks after th e last day of PE (including tapering) 
sampling may be done at the weekly visit, even if not exactly 1 or 3 weeks.  
The resulting data will be provided to the Investigator for information at the end of the study. 
In case an investigator has no access to similar assays and availability of ADAMTS13 and anti-ADAMTS13 antibody titre are considered essential for clinical decision making, an ad 
hoc determination of the results can be organised (under supervision of the country coordinator).  
Platelets and LDH will b e measured from blood sampling on days 3 and 7 following the 
conclusion of study drug administration. If at any time the platelet count falls below 70% of the last platelet count prior to cessation of study drug administration, with concomitant LDH > 1.[ADDRESS_557758]: the subject will be considered at risk of a relapse and she/he will need to be 
closely monitored by [CONTACT_7893].  
When practical and logistical circumstances prevail, the Investigator can decide to hospi[INVESTIGATOR_148490] a subject for observation in order to facilitate the follow up during these [ADDRESS_557759] -study 
drug treatment period. Such a hospi[INVESTIGATOR_11956], organised only for practical and logistic reasons and not triggered by [CONTACT_439934], should be considered as an elective hospi[INVESTIGATOR_439877], and not as an AE or SAE (please refer to section 9.1.1) .  
 
Assessments scheduled in case of TTP relapse 
In case of TTP relapse, defined as de novo event of TTP that occurs later than [ADDRESS_557760] daily PE, the assessments described under “daily PE for the treatment of relapse” 
are scheduled (see Table 14). Note that there are no “post -daily PE (including tapering)” 
assessments, instead, follow -up should continue per protocol. In case a follow -up visit was 
scheduled during the daily PE period, this visit is omitted.  
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 88 /127  Table 14: Schedule of assessments during daily PE for the treatment of a relap se. 
Assessment/Activity Daily PE for the treatment of a relapse  
Treatment with study drug  No 
Concomitant medication recording other than PE -related treatment  all 
PE detailsa all 
Patient review/clinical assessment, including vital signs  daily 
AE record ing daily (all)  
Glasgow Coma Score  No 
Neurocognitive battery  no 
Modified ITP bleeding score daily 
Clinically relevant bleeding  No  
12-lead ECG  daily if abnormal at baseline.  
on day 1 and day 4  
Blood chemistry (local lab)  daily pre- PE 
Haematology (local lab)  daily pre- PE 
Coagulation variables (local lab)  Mon, Wed, Fridays  
Cardiac marker (TnT or TnI) (local lab)  daily pre -PE  
if value > ULN in baseline or at day 1  
BNP or NT proBNP (local lab)   Mon, Wed, Fridays pre -PE 
if value > ULN in baseline or at day 1  
Brain damage markers (NSE, Sβ100) (central lab)  No 
PK (central lab)  No 
RICO (central lab)  No 
vWF (central lab)  No 
FVIII chromogene (central lab)  No 
ADA (central lab)  No 
ADAMTS13 and anti -ADAMTS13 antibody titre (central lab)  No 
Spent plasma retrieval No Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 89/127  Assessment/Activity Daily PE for the treatment of a relapse  
Recuperate nurse sheet and/or AE diary NA 
a Including concomitant medication related and simultaneous to PE procedure.  
Blood chemistry includes glucose, AST, ALT, LDH, CRP, creatinine, urea (BUN), uric acid, protein, albumin, haptoglobin, Na, K , Ca,  Mg and Cl.  
Haematology includes haemoglobin, haematocrit, MCV, MCH, MCHC, full blood count including RBC, WBC, differential, reticulocytes, optical platelet count and immature 
platelet fraction. Coagulation variables include fibrinogen, aPTT, PT, INR, vWF:Ag and FVIII (chromogene or alternative method).  
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 90 /127  8.1.4  Unscheduled Additional Visit  
 
In case of unscheduled additional visits, the following assessments will be performed at a minimum ( Table 13 ): 
• Concomitant medication taken since the previous visit must be recorded on the Concomitant Medications page of the CRF. Concomitant medications initiated, stopped, up- titrated or down- titrated for an AE will also be recorded on a specific 
Concomitant Medications page of the CRF. Transfusion of RBC units will be recorded as concomitant medication 
• Clinical assessment will include physical examination and vital signs (blood pressure and heart rate at rest, body temperature)  
• Bleeding score according to the modified ITP bleeding scor e 
• Assessment of clinically relevant bleeding 
• AE recording 
• 12-lead ECG  
• Blood sampling for chemistry will include the following: glucose, AST, ALT, LDH, CRP, creatinine, urea (BUN), uric acid, protein, albumin, Na, K, Ca, Mg and Cl (local 
laboratory)  
• Blood sampling for haematology will include the following: haemoglobin, haematocrit, 
MCV, MCH, MCHC, full blood count including RBC, WBC, differential, reticulocytes, optical platelet count and immature platelet fraction (local laboratory). In case optical platel et counts are not available, they can be replaced by [CONTACT_439935]. If not available in the local laboratory, immature platelet fraction measurements can be omitted  
• Blood sampling for coagulation variables will include: fibrinogen, aPTT, PT, INR, vWF:Ag and FVIII chromogene (local laboratory). In case FVIII chromogene is not available in the local laboratory, it can be replaced by [CONTACT_439930] (e.g. one stage clotting assay)  
• Blood sampling for markers for cardiac cell death: Troponin T (local laboratory). In case Troponin T is not available in the local laboratory, it can be replaced by 
[CONTACT_439931] I 
• Blood sampling for markers for heart failure: BNP or NT- proBNP (local laboratory)  
• Blood sampling for markers for brain damage: NSE, S β100 (central laboratory)  
• Blood sampling for PK and RICO, if applicable (additional visit during period of administration of study drug (central laboratory) 
• Blood sampling for vWF, FVIII chromogene, and for ADA (central laboratory)  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 91 /127  • Blood sampling for ADAMTS13 and anti -ADAMTS13 antibody titre (central laboratory) 
• Recuperate the nurse sheet and/or AE diary, if applicable (additional visit post -
hospi[INVESTIGATOR_2345])  
 
8.1.5  Exacerbation and relapse visits  
 
Additional information on the assessments  performed during TTP exacerbation and relapse 
is included in sections 8.1.2 and 8.1.3 respectively.  
 
8.2 Assessment of Efficacy  
 
8.2.1  Clinical Outcome  
 
• Time -to-response of treatment, defined by a recovery of platelets ≥ 150,000/µL. This 
response must be confirmed at 48 hours after the initial reporting of platelet recovery 
above 150,000/µL by a de novo measure of platelets ≥ 150,000/µL and LDH ≤ [ADDRESS_557761]  
• Number of subjects with complete remission 
• Number of (subjects with) exacerbations of TTP and time to first exacerbation of TTP. Exacerbation is defined as recurrent thrombocytopenia following a response and requiring a re -initiation of daily PE treatment after ≥ 1 day but ≤ [ADDRESS_557762] 
daily PE.
1 
• Number of subjects relapsing of TTP (defined as de novo event of TTP that occurs 
later than [ADDRESS_557763] daily PE) for a maximum of [ADDRESS_557764] 
relapse of TTP  
• Daily PE data, including serious adverse events (SAEs) related to daily PE treatment  
• Neurocognitive function, as measured by a neurocognitive test battery, at complete remission and at [ADDRESS_557765] 
• Improvement of organ dysfunction and improvement of TTP related signs and 
symptoms  
• Total mortality within the daily PE treatment period and within the subsequent study 
drug treatment  period (including tapering)  
• Determination of biomarkers of TTP including but not limited to disintegrin- like and 
metalloprotease with thrombospondin repeats 13 (ADAMTS13) levels and anti -
ADAMTS13 antibody titres (see also PD assessments) Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 92 /127  [IP_ADDRESS]  Outcomes of Speci al Interest  
 
[IP_ADDRESS].1  Plasma exchange  
 PE is the principal therapy of this pathology. PE will be described and recorded in detail 
throughout the study. This includes the initial series of PE sessions, as well as any further PE 
sessions that may be administered after interruption of the previous session. All PE sessions arising prior to remission and ultimately within 1 year after inclusion into the study will be recorded.  
 The following minimum details will be required, for each PE session:  
1. Start date/time and end date/time of each procedure  
2. Completion as planned or interruption needed and reason thereof  
3. Plasma replacement  
a. Type of plasma product used 
b. ABO group used  
c. Total number of units used during the PE session  
d. Total volume used for plasma replacement during the PE  session 
4. Anticoagulant administered, if any, for the PE session 
5. Concomitant medication administered specifically as part of the PE procedure and during the course of the PE session will be recorded separately. Other concomitant medication, such as methylprednisone will be reported in the concomitant medication other than PE -related medication.  
Medication given in response to a PE -related AE (i.e. antibiotic administration due to 
a central line infection) will be reported in the concomitant medication other than PE -
related medication. This also includes immunosuppressive and other treatments adjunctive to PE (i.e. methylprednisone, rituximab).  
 [IP_ADDRESS].2  Transfusion of RBC  
 Transfusion of RBC will be described by:  
• Number of RBC units  
• Date/time of administration 
• This data is entered in the concomitant medication other than PE.  
  
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 93 /127  [IP_ADDRESS].3  Peripheral and/or central blood line placement and replacement for daily PE  
 
Each placement and replacement will be described for:  
• Central or peripheral access  
• Implant date/time and removal date/time of each central access  
• Material used and anatomical point of entry  
• Results of culture after removal  
 
[IP_ADDRESS].4  Supportive measures  
 Supportive measures will be described in concomitant medication other than PE.  
 [IP_ADDRESS].5  Modified ITP bleeding score  
 This bleeding score  is described in Section 8.3.3 . 
 [IP_ADDRESS].[ADDRESS_557766] battery is described in the Section 8.3.6 . 
 
8.2.2  Pharmacodynamics 
 
Sampling  
Pharmacodynamic parameters listed below will be assessed by a central laboratory. Blood samples for laboratory parameters will be collected as scheduled in Table 10 (screening and 
baseline) , Table 11  (treatment phase) and Table 13 (follow -up).  
• RICO (conducted at central lab)  
• vWF, including vWF:Ag and vWF propeptide (conducted at central lab) 
• FVIII chromogene (conducted at central lab)  
 Instructions for the handling of laboratory samples are in a separate Laboratory Manual.  
 
Labelling and shippi[INVESTIGATOR_439878]. The tubes will 
be labelled and will carry the following information:  
• Type of sample, e.g., blood, urine, etc.  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 94 /127  • Study number  
• Subject number  
• Sample number  
• Scheduled time of sampling 
 Instructions for the handling of laboratory samples are in a separate Laboratory Manual.  
 
8.2.3  Laboratory Markers of Disease 
 
Disease markers listed below will be assessed by a central or local laboratory. Blood samples will be collected as scheduled in Table 10 (screening and baseline) , Table 11  
(treatment phase) and Table 13 (follow -up).  
• ADAMTS13 and anti- ADAMTS13 antibody titre (central laboratory)  
• Cardiac marker (TnT or TnI)  
• BNP or NT proBNP 
• Brain damage markers (NSE, Sβ100) (central laboratory)  
• PD (see Section 8.2.2  above)  
 
8.3 Assessment of Safety 
 8.3.1  Safety Laboratory Monitoring  
 Blood samples for laboratory parameters will be collected as scheduled in Table 10  
(screening and baseline), Table 11  (treatment phase) and Table 13  (follow -up).  
All safety laboratory parameters will be performed at each local site laboratory. For each local laboratory, the Investigator will provide Ablynx with the name, professional degree and curriculum vitae of the laboratory director, a copy of the laboratory's certification- and the 
normal ranges for  each parameter being evaluated in the study. These laboratory references 
must be forwarded to Ablynx before study start and updated whenever necessary. However, 
the Investigator will request that the clinical laboratory does not change any normal range 
during the course of the study.  
Instructions for the handling of laboratory samples are in a separate Laboratory Manual.  
Virus serology will be measured at screening only. The samples will be sent to the local laboratory as soon as possible after blood sampl ing. 
Laboratory data will be transmitted electronically from the laboratory, to the study site. A print-out of the laboratory results will be added to the source documents. Each parameter 
outside the normal range will be assigned as H (high) or L (low) on the laboratory sheet. The Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 95 /127  Investigator has to interpret each “outside the normal range” value as n.c.s. (not clinically 
significant) or c.s. (clinically significant). In the latter case the Investigator has to give a 
comment and the deviation is judged as an AE or SAE as appropriate.  
 
Laboratory parameters  
For all the items below the name [CONTACT_439968], units of each parameter and normal range 
(lower limit of normal (LLN) and ULN) must be specified.  
• Haematology  
o Full blood count, including haemoglobin, haematocrit, MCV, MCH, MCHC, full 
blood count including: RBC, WBC and differential blood count  
o Reticulocytes  
o Optical platelet count (if not available, can be replaced by [CONTACT_439936]) 
o Immature platelet fraction (can be omitted)  
• Blood chemistry  
o Glucose  
o Bilirubin (total)  
o AP 
o AST 
o ALT 
o LDH 
o CRP  
o hCG (for women, only if urine pregnancy test is not feasible or inconclusive)  
o Rheumatoid factor  
o Antinucleic acid 
o Iron, ferritin, transferrin  
o Creatinine, urea (BUN), uric acid  
o Protein, albumin  
o Na, K, Ca, Mg, Cl  
• Urinanalysis  
o pH  
o Specific gravity  
o Protein  
o Glucose  
o Ketones  
o Bilirubin  
o Blood  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 96 /127  o Nitrite  
o Urobilinogen  
o Leukocytes  
• Urine pregnancy test for female subjects (hCG only)  
• Virus serology  
o HIV1 and HIV2 antibodies at screening 
o Surface antigen of HBV (HbsAg) and HCV antibodies at screening 
• Coagulation variables  
o aPTT 
o PT 
o INR 
o Fibrinogen  
o vWF:Ag  
o FVIII chromogenic or alternative method (e.g. one stage clot test)  
o Lupus anticoagulant 
o Anticardiolipin antibodies (antiphospholipid)  
• Blood typi[INVESTIGATOR_007] (ABO and Rh) and DAT  
 
8.3.2  P hysical Examination and Vital Signs  
 
A complete patient review and clinical assessment including vital signs  will be performed at 
screening, during treatment phase and during follow -up, as indicated in Table 10, Table 11  
and Table 13, respectively.  
 Blood pressure (systolic and diastolic) shall always be measured on the same arm (preferentially on the left arm). Heart rate measurements will be performed manually. Body temperature will be measured by [CONTACT_439937]. Measurements shall be recorded from the subject in the lying position after having rested for a 5-minute period.  
 After drug administration, inspections for vascular effects will focus on checks for bruising, 
haematomas, bleeding at injection and puncture sites and shaving nicks, gingival haemorrhage after brushing teeth, epi[INVESTIGATOR_439879]. Specifi c questioning will be performed on whether subjects have experienced 
bleeding or bruises since the last examination.  
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 97 /127  8.3.3  Bleeding Events  
 
Clinically relevant bleeding  
Incidence of clinically relevant bleeding will be reported. Clinically relevant bleeding is 
defined as moderate to severe (including life- threatening) bleeding requiring urgent medical 
and/or surgical intervention.  
Modified ITP bleeding score 
Bleeding will also be measured using a modified version of the immune thrombocytopenic 
purpura (ITP) bleeding score. The rationale for using a modified version of the ITP bleeding 
score is the following. Both the WHO bleeding scale and other bleeding scales used in the 
frame of cardiac intervention or treatment of venous thromboembolism include bleeding or blood loss requiring transfusion of packed RBC or whole blood as a severity factor. It is 
common for subjects undergoing PE to need transfusions, even without apparent bleeding. The ITP bleeding score
27 does not include transfusion data. It is expected to be more 
sensitive than the other bleeding scales mentioned above. The modified ITP bleeding score is the sum of the scores for each line ( Table 15 ). 
 
Table 15: Modified ITP bleeding score . 
Grade  0 1 2 
Skin: petechiae  None  Scattered petechiae  Diffuse petechiae  
Skin: ecchymosis  None  1-5 bruises  >5 bruises with size > 2cm  
Oral None  1 blood blister or >5 
petechiae or gum bleeding 
<5 min  Multiple blood blisters or gum bleeding >5 min  
Epi[INVESTIGATOR_439880] <5 min (per 
epi[INVESTIGATOR_1865])  Epi[INVESTIGATOR_3940] >5 min (per epi[INVESTIGATOR_1865])  
Ocular  None  
Subconjunctival 
haemorrhage   
Intracranial  None   Haemorrhage  
Gastrointestinal  None  Blood when wipi[INVESTIGATOR_439881], or very heavy period  
Pulmonary  None  Haemoptysis  Haemorrhage  
 
Clinically relevant findings that are observed prior to study drug initiation must be recorded 
on the relevant Medical History source documents page. Abnormalities in local tolerability will be reported via AE reporting throughout the trial.  Clinically relevant findings found after study Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 98 /127  drug initiation and meeting the definition of an AE (new AE or worsening of previously 
existing condition) must be recorded on an AE page of the source documents.  
 
8.3.4  Cardiovascular Monitoring  
 
12-lead ECGs will be performed at the time points specified in Table 10 (baseline), Table 11  
(treatment phase) and Table 13 (follow -up). ECGs will be conducted with respect to the 
following procedure. Subjects will be in horizontal position during the measurements. ECGs will be evaluated and classified as normal/abnormal. In case of “abnormal”, the abnormality has to be described. Heart rate, PR, QRS, QT and QTc (Bazett) will be entered into the 
database. Bazett is automatically calculated by [CONTACT_439938]-out. Fridericia and RR will be calculated from the available data. For the baseline ECG, 
one recording will be made. The 12- lead ECGs will be recorded after the subjects  have 
rested for at least five minutes in supi[INVESTIGATOR_2547]. Six limb leads, as specified by [CONTACT_439939] (I, II and III) and Goldberger (aVR, aVL, aVF), and six precordial leads (V1– V6), according to 
Wilson, will be used. The ECG will be recorded at a paper speed of 25 mm/s and a standard calibration of 1 mV (=  10 mm). Each ECG will include the following information: identification 
of each lead, study number, subject number, paper speed, voltage calibration as well as date and time of the recording. This procedure will also be followed for unscheduled visits.  
 
8.3.5  Glasgow Coma Score  
 
The Glasgow Coma Score will be determined using the Glasgow Coma Scale (original scale), which is a neurological  scale  that measures the conscious state of the subject. The 
best eye, verbal  and motor  responses will be scored according to the scale, and the separate 
scores added up to obtain the final score, ranging from 3 to 15.  
 
8.3.6  Neurocognitive Battery  
 
The neurocognitive battery, consisting of the CNTB and two manually -administered, pencil -
and-paper tests (Category Fluency and Letter Fluency), will be administered at the following 
time point s:  
• Baseline (only if the level of consciousness and attentiveness of the subject permits and environmental factors are appropriate to support neurocognitive testing)  
• Treatment phase  
o Once as soon as possible during the PE treatment phase (i.e., as soon as the 
level of consciousness and attentiveness of the subject permits and Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 99 /127  environmental factors are appropriate to support neurocognitive testing) and 
only if the subject’s condition did not allow to perform the CNTB at baseline 
• Follow -up 
o At 3 days ± 1 days  
o At 12 months ± 15 days  
 
Only appropriately trained and Sponsor -approved testers may administer the neurocognitive 
battery to study subjects. The Principal Investigator [INVESTIGATOR_439882]/her staff conduct the testing according to the protocol and any training guidelines 
provided for the battery. When testing occurs in the clinic setting, subjects should be tested in the same room under constant environmental conditions such as lighting, heating and noise. When testing occurs outside of the clinic setting, e.g., at bedside, the tester should ensure that the subject is able to sit upright and interact with computer touch screen and the testing area is quiet and relatively free of extraneous, distracting stimuli. Subjects who wear hearing  devices or eyeglasses for reading will wear them when completing the 
neurocognitive assessments.   
[IP_ADDRESS]  CNTB  
 The CNTB is an assessment tool for the computerised testing of neuropsychological function. The standard CNTB has [ADDRESS_557767]. The customised set of modules is administered in a standardised order and with standardised stimulus durations. In this study, 6 CNTB modules will be administered (with approximate time to administer) in the sequence that follows:  
 
Word List Learning and Selective Reminding (WLL/SR)   approx. 7 minutes  
Choice Reaction Time (CRT)      approx. 2.5 minutes  
Visual Memory (VMEM)       approx. 5 minutes  
Simple Reaction Time (SRT)      approx. 2 minutes  
Working Memory (WMEM)      approx. 2.[ADDRESS_557768] Learning and Delayed Recall (WLL/DR)   approx. [ADDRESS_557769] will be administered to evaluate verbal learning and memory (verbal rote memorisation). It has 2 components: an initial learning component utilising selective reminding (WLL/SR) and a delayed recall component (WLL/DR). A test requiring memory of novel shapes (VMEM) will be given to evaluate visual learning and memory (visual rote Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 100/127  memorisation). Information processing speed will be measured by [CONTACT_439940]. 
The CRT, together with a WMEM test, will be used to measure complex attention and 
concentration. This customised CNTB battery will take approximately 21 minutes to complete.  
 
[IP_ADDRESS]  Category Fluency Test  
 In this test, subjects are required to produce as many examples of a given category (e.g., animals, vegetables) as quickly as possible within a specified time period. A higher number indicates better performance. The category fluency test assesses rapid language g eneration 
and depends on sustained attention, verbal intelligence, cognitive flexibility and efficiency of semantic processing. The category fluency test takes approximately 2- 3 minutes to 
administer.  
 
[IP_ADDRESS]  Letter Fluency Test  
 This test measures the number of correct words generated by [CONTACT_439941], 
where the generated words are required to begin with three predefined letters (which differ, 
depending on the language in which the scale is being used). A higher number indicates a better performance. The letter fluency test assesses rapid language generation and depends on sustained attention, verbal intelligence, cognitive flexibility and efficiency of semantic processing. The letter fluency test takes approximately 5- [ADDRESS_557770]’s CRF.  
Any clinically significant changes in laboratory parameters and all deviations of coagulation 
parameters outside normal range will be recorded as (an) AE(s) in the relevant section of the 
CRF.  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 101/127  The non- leading question "Have you felt different in any way over the last few days?" will be 
asked at baseline and the question "Do you feel different in any way since starting the new 
treatment/the last assessment?" will be asked at regular intervals throughout the study. The responses will be recorded in the subject’s CRF.  
The nature of each event, date and time of onset, duration, severity and relationship to treatment should be established. Details of changes to the dosage schedule or any corrective treatment should be recorded on the appropriate pages of the CRF. The Investigator should follow -up subjects with AEs until the event has subsided 
(disappeared) or until the condition has stabilised. Reports relative to the subject’s subsequent course must be submitted to the clinical study monitor.  
For more details, r efer to section 9. 
 
8.3.8  Immunogenicity  
 
ADA in serum will be determined by [CONTACT_439942]. Immunogenicity testing will be performed on the timepoints indicated in Table 10 (screening and baseline), Table 11  
(treatment phase) and Table 13 (follow -up). The sample analysis will be done by [CONTACT_439943]. 
A full description of the ADA assay is provided in the separate Laboratory Manual.  
A separate immunogenicity report will be prepared and presented as an Appendix to the 
Final Clinical Study Report. 
  
8.4 Pharmacokinetic Assessment  
 
8.4.1  Sampling  
 
Blood sampling for PK assessment will take approximately 1 minute. A detailed overview for the sampling times is presented in Table 10  (screening and baseline), Table 11 (treatment 
phase) and Table 13  (follow -up). 
In case several study procedures are scheduled at the same time point, the following sequence should be followed: asking for AEs, ECG, vital signs, PK blood sampling and blood sampling for clinical laboratory tests. Enough time should be reserved for all assessments to be performed so that the administration of study drug and the PK blood sampling is done at the scheduled time point.  
All assessments have to be scheduled in a way that the time point of PK sampling is strict ly 
kept as displayed in Table 10, Table 11 and Table 13. 
Instructions for the handling of laboratory samples are in a separate Laboratory Manual.  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 102/127  8.4.2  Labelling and Shippi[INVESTIGATOR_439883]. The tubes will be labelled and will carry the following information:  
• Type of sample, e.g., blood, urine, etc.  
• Study number  
• Subject number  
• Sample number  
• Scheduled time of sampling 
 Instructions for the handling of laboratory samples are in a separate Laboratory Manual.  
 8.4.[ADDRESS_557771] demographics, laboratory parameter values, 
and other covariates on the pharmacokinetics of ALX -0081 will be explored.  The results of 
the population PK analysis will be reported in an independent Modeling and Simulation 
report.  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 103/127  9. SAFETY DEFINITIONS A ND REPORTING REQUIRE MENTS  
 
9.1 Adverse Events 
 
9.1.1  Definitions of Adverse Events  
 
An AE is “ any untoward medical occurrence in a patient or clinical investigation subject 
administered a study drug and which does not necessarily have a causal relationship with 
this treatment”. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not related to the study drug.  
A treatment -emergent AE is any AE temporarily associated with the use of a study drug, 
whether or not considered related to the study drug.  
AEs include:  
• Exacerbation of a pre- existing disease  
• Increase in frequency or intensity of a pre -existing epi[INVESTIGATOR_42861] 
• Disease or medical condition detected or diagnosed after study drug administration even though it may have been present prior to the start of the study  
• Continuous persistent disease or symptoms present at baseline that worsen following the start of the study  
• Lack of efficacy in the acute treatment of a life- threatening disease  
• Events considered by [CONTACT_116344] -mandated procedures  
• Abnormal assessments, e.g., ECG, vital signs or physical examination findings, must be reported as AEs if they represent a clinically significant finding that was not present at baseline or worsened during the course of the study  
• Laboratory test abnormalities must be reported as AEs if they represent a clinically significant finding, symptomatic or not, which was not present at baseline or worsened during the course of the study  
AEs do not include:  
• Medical or surgical procedure, e.g., surgery, endoscopy, tooth extraction, transfusion. However, the event leading to the procedure is an AE. If this event is serious, the procedure must be described in the SAE narr ative  
• Pre-existing disease or medical condition that does not worsen 
• Situations in which an adverse change did not occur, e.g., hospi[INVESTIGATOR_439884]/or convenience reasons, or elective Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 104/[ADDRESS_557772].  
• Overdose of either study drug or concomitant medication without any signs or 
symptoms. However, overdose must be mentioned in the Study Drug Log 
 
9.1.2  Definition of Adverse Reaction (AR)  
 
An AR is a noxious and unintended response to a study drug irrespective of the dose administered.  
All ARs are judged by [CONTACT_96949] a reasonable causal relationship to the study drug. The expression reasonable causal relationship means to convey in general that there is evidence or argument to suggest a causal relationship.  
An unexpected adverse reaction is an AR, the nature or severity of which is not consistent with the information available on the study drug (i.e. the current Investigator's Brochure).  
 
9.1.3  Intensity of Adverse Events  
 
The intensity of clinical AEs is graded on a three- point scale: mild, moderate, severe and 
reported on specific AE pages of the source documents.  
If the intensi ty of an AE worsens during study drug administration, the AE will be closed and 
a new AE with enhanced severity will be generated in the source documents. If the AE 
lessens in intensity, no change in the severity is required.  
If an AE occurs during a washout or placebo run- in phase and afterwards worsens during the 
treatment phase, a new AE page must be filled in with the intensity observed during study drug administration.  
• Mild 
Event may be noticeable to subject; does not influence daily activities; usually does not require intervention 
• Moderate  
Event may make subject uncomfortable; performance of daily activities may be influenced; intervention may be needed  
• Severe  
Event may cause noticeable discomfort; usually interferes with daily activities; subject may not be able to continue in the study; treatment or intervention is usually needed  
A mild, moderate or severe AE may or may not be serious. These terms are used to describe the intensity of a specific event (as in mild, moderate or severe myocardial infarc tion). Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 105/127  However, a severe event may be of relatively minor medical significance (such as severe 
headache) and is not necessarily serious. For example, nausea lasting several hours may be 
rated as severe, but may not be clinically serious. Fever of 39°C that  is not considered 
severe may become serious if it prolongs hospi[INVESTIGATOR_359228] a day (see Section [IP_ADDRESS] ). 
Seriousness rather than severity serves as a guide for defining regulatory reporting obligations.  
 
9.1.4  C lassification according to CTCAE  
 
AEs will be classified by [CONTACT_439944] v4.0 in addition to severity.  
 
9.1.5  Relationship to Study Drug  
 
AEs should be assessed by [CONTACT_439945] a reasonable possibility o f causal relationship to the study drug and reported as either related or unrelated.  
• Related to study drug 
This category applies to any AE (serious or not) with a causal relationship to the use 
of the study drug such as:  
− The event occurred in close temporal relationship to study drug administration 
− The event abated (diminished) or disappeared when treatment with the study drug was down- titrated, interrupted or discontinued 
− The event re -occurred when treatment was re- introduced 
− Cannot be explained by [CONTACT_439946]’s clinical condition 
 
• Possibly related to study drug 
This category applies to any AE (serious or not) that appears to have a reasonable 
possibility of causal relationship to the use of the study drug (i.e., a relationship 
cannot be ruled out). Guidelines to determine whether an event might be considered possibly related include (but are not limited to) the following:  
− Is a clinical event, including laboratory test with clinically significant abnormalities, within a reasonable time sequence to administration of the study drug 
− Environmental factors such as clinical state and other treatments could equally have caused the event  
− Information on study drug withdrawal may be lacking or unclear  
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 106/127  • Unlikely/Not related to study drug  
This category applies to any AE (serious or not) that does not appear to have a 
reasonable relationship to the use of study drug (see above guidelines).  
According to current knowledge, the likelihood of a causal connection with the study 
drug is minimal.  
 
9.1.[ADDRESS_557773] be recorded until end of follow -up (1y), or 
until subject withdrawal. Subjects entry into the study is defined as the time at which informed 
consent is obtained. All subsequent AEs, irrespective of whether no drug, study drug or placebo was administered, must be recorded on specific AE pages of the respective CRF, regardless of whether or not they are considered to be study drug related. AEs occurring from study drug initiation until [ADDRESS_557774] study drug discontinuation (inclusive) are defined 
as treatment emergent.  
 
9.1.[ADDRESS_557775] be followed until resolution if possible.  
 
 
9.2 Serious Adverse Events/Serious Adverse Reaction  
 9.2.1  Definitions  
 
[IP_ADDRESS]  Serious Adverse Events/Serious Adverse Reaction (SAE/SAR)  
 
An SAE or SAR is defined by [CONTACT_5787] (ICH) 
guidelines as any AE fulfilling at least one of the following criteria:  
• Fatal  
• Life-threatening 
• Requiring subj ect's hospi[INVESTIGATOR_15574] 
• Resulting in persistent or significant disability or incapacity 
• Congenital anomaly or birth defect  
• Medically significant or requires intervention to prevent at least one of the outcomes 
listed above Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 107/[ADDRESS_557776] and may require medical or surgical intervention to prevent one of the outcomes listed in the definitions above.  
The reference safety document to assess whether or not an SAE should be reported by [CONTACT_439947], Ethics Committees (ECs)/IRBs and Investigators in an expedited fashion, is the Investigator's Brochure.  
 
[IP_ADDRESS]  H ospi[INVESTIGATOR_439885] a hospi[INVESTIGATOR_359230]/or emergency room.  
An additional overnight stay defines a prolongation of existing hospi[INVESTIGATOR_11956].  
The following is not considered an SAE and should be reported as an AE only:  
• Treatment on an emergency or outpatient basis for an event not fulfilling the definition of seriousness given above and not resulting in hospi[INVESTIGATOR_439886]: 
• Hospi[INVESTIGATOR_439887], social and/or convenience reasons  
• Standard monitoring of a pre- existing disease or medical condition that did not 
worsen, including elective hospi[INVESTIGATOR_439888] -up when practical and logistical circumstances exist  
• Elective treatment of a pre- existing disease or medical condition that did not worsen, 
e.g., hospi[INVESTIGATOR_439889], elective hip replacement for arthritis  
 
[IP_ADDRESS]  Serious Adverse Events Related to Study -mandated Procedures  
 
SAEs related to study -mandated procedures are defined as SAEs that appear to have a 
reasonable possibility of causal relationship (i.e., a relationship cannot be ruled out) to study-
mandated procedures (excluding administration of study drug) such as discontinuation of subject's previous treatment during a washout period or complication of a mandated invasive procedure (e.g., blood sampling, heart catheterisation) or car accident on the way to the 
hospi[INVESTIGATOR_34092] a study visit, etc.  
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 108/127  [IP_ADDRESS]  Suspected Unexpected Serious Adverse Reaction (S[LOCATION_003]R)  
 
All suspected ARs related to a study drug which occur in the concerned study, and that are both unexpected and serious are classified as suspected unexpected serious adverse reactions (S[LOCATION_003]Rs).  
 
9.2.2  Reporting of Serious Adverse Events  
 
[IP_ADDRESS]  Before Study Drug Initiation  
 
SAEs occurring after signature [CONTACT_439969].  
 
[IP_ADDRESS]  During Study Drug Administration  
 All SAEs regardless of causal relationship must be reported, including those related to study -
mandated procedures. These SAEs occurring during study drug administration, i.e., between study drug initiation and follow -up after study drug discontinuation (as per Section [IP_ADDRESS]), 
are defined as treatment emergent SAEs. Elective hospi[INVESTIGATOR_439890]-reportable events and should only be recorded as clinical finding.  
 These SAEs are reported on SAE forms and on the AE pages of the respective CRF.  
 
[IP_ADDRESS]  After Study Drug Discontinuation  
 All SAEs occurring within and including [ADDRESS_557777] administration of study drug are reported until end of follow -up (1y), or  until subject withdrawal (as per section 5.4.2).  
 
[IP_ADDRESS]  Reporting Procedures by [CONTACT_439948]’s Drug Safety department within 24 hours of the Investigator's knowledge of the event. 
These SAE forms must be faxed to the CRO’s Drug Safety responsible (see contact [CONTACT_439949] 5). The Investigator must complete the SAE form in English (unless otherwise Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 109/127  specified) and assess the relationship to study drug. Such preliminary reports will be followed 
by [CONTACT_439950][INVESTIGATOR_3103], autopsy reports, 
hospi[INVESTIGATOR_110160]. Follow -
up information about a previously reported SAE must also be reported within 24 hours of 
receiving it. The CRO’s Drug Safety department may contact [CONTACT_439951].  
 Suspected (considered related to the study drug) and Unexpected (not previously described in the reference safety document), S[LOCATION_003]Rs will be expedited by [CONTACT_439952],  ECs/IRBs, as appropriate.  
 
9.2.[ADDRESS_557778] be followed until resolution or death, including those still ongoing at the End- of-
Study visit.  
 
9.2.4  Reporting Procedures by [CONTACT_439953] (or IRB) concerned as soon as possible but within a maximum of 15 days 
(fatal or life -threatening S[LOCATION_003]Rs within a maximum of 7  days) of first knowledge by [CONTACT_439954].  
Relevant follow -up information of fatal or life -threatening S[LOCATION_003]Rs will be communicated 
subsequently within an additional eight days.  
Once a year throughout the clinical study, a listing of all suspected SARs (expected and 
unexpected) which have occurred and a report on the safety of the participating subjects 
(Annual Safety Report) will be provided to the competent Regulatory Authority and the competent IEC (or IRB).  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 110/127  10. STATISTICAL PROCEDURES 
 
An SAP will be written to provide details of all statistical analyses. The SAP will be finalised before database lock and will comprise all methods and tests applied for analysis of the data  
The different study populations defined for endpoint analysis are described below.  
 
10.1 Study Populations  
 
Populations for the primary and secondary endpoint analyses  
The primary analysis population will be the intent -to-treat (ITT) population, which will consist 
of all randomised subjects according to the randomised treatment assignment. In addition, for the efficacy analyses, the per protocol population (PP) will be used. The PP population will be a subset of the ITT population and will consist of all randomised subjects, according to the randomised treatment assignment, with exclusion of all major protocol violators . 
 
Population for the s afety analysis  
The safety population will consist of all subjects who received at least one dose of study drug, with treatment assignment designated according to actual treatment received.  
 
Population for the PK analyses  
The PK analyses will be performed on the PK population, which will consist of all subjets who have received study drug and for whom the primary PK data are considered to be sufficient and interpretable.   
 
10.2 Statistical and Analytical Plan for Pharmacokinetic Evaluation  
 For the sparse sampling, descriptive statistics (mean, median, min, max, standard deviation and % coefficient of variation (CV)) will be calculated per sampling day and sample collection interval. A separate Data Analysis Plan (DAP) will be prepared prior to the population PK 
analysis . 
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 111/127  10.3 Evaluation of Safety and Tolerability Parameters  
 
All safety parameters (physical examination, vital signs, bleeding, ECG -parameter, 
biochemistry/haematology and ADA evaluations, concomitant medications (including PE characteristics) and AEs) will be summarised descriptively by [CONTACT_3148]. Quantitative variables will be described by n, mean, standard deviation, median, minimum and maximum. Qualitative variables will be described by [CONTACT_439955]. Additionally, shift tables will be provided for the safety laboratory parameters 
(within, below or above normal range) from pre- study to post -dose.  
The AEs will be coded according to MedDRA and tabulated by [CONTACT_9313], preferred term and lower level term. An AE will be referred to by [CONTACT_439956], i.e. any AE occurring before the dosing will be counted as a baseline AE and will be considered as a treatment -emergent AE only if the severity or relation to drug 
changes.  
No for mal statistical testing will be performed on the safety data.  
 
10.4 Determination of Sample Size  
 For the sample size calculation SAS version 9.2 has been used.  
The primary endpoint of time- to-response of blood markers (defined as time- to-response) is 
monitored in a survival setting.  
 
Sample Size Calculation The time- to-response of blood markers is monitored in a survival 
setting. The primary endpoint time- to-response of blood markers comprises recovery of 
platelets ≥ 150,000/µL. Accrual period is taken as 1.5 years. Zero to time- to-event  period is 
set at 30 days. As median time- to-response for the control group we take 6 days (this 
information is calculated based upon Bandarenko et al.
28). For the treated group with 
ALX-0081 we assume a 44% risk reduction corresponding to a reduction in median time to 
event of 2. [ADDRESS_557779] of control versus experimental (ALX -0081) 
treatment thus equalling to 6/3. 36=1.786. The sample size calculations are performed based 
on a log- rank test, aiming for a power of  80%, tested 1- sided at 2.5% significance level with 
1:1 randomisation. Note that we assume that 15% of subjects would be lost -to-follow -up. The 
latter is justifiable because the active follow -up period only equals 30 days. Based on the 
above described ass umptions a sample size of 110 subjects is required.  
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 112/127  10.5 Assessment of Primary Endpoint  
 
The primary endpoint (i.e. time- to-response of blood markers comprising recovery of 
platelets  ≥ 150,000/µL) will be formally assessed by [CONTACT_3553] a survival analysis. An SAP 
will be prepared before closing the database and will comprise all methods and tests applied 
for analysis of the data. Assessment of the primary endpoint is performed by [CONTACT_2329] a one -sided log -rank test at 2.5% 
significance level. A Kaplan- Meier (KM) analysis with time -to-response as the endpoint and 
treatment group as the independent variable, and stratified for absence/presence of one PE session prior to randomisation, will be performed on the ITT and PP populations. An 
observation is censored if the observation does not meet the defined time interval of [ADDRESS_557780] administration of study drug medication, due to any cause of loss -to follow -up 
(including death), or endpoint not being reached within the defined time interval.  
The log -rank test is one-sided because inhibition by [CONTACT_439957] -0081 of vWF is expected for all 
subjects. Indeed, as described in section 2.4.2, 100% of subjects receiving a SD s.c. injection of 8 mg already had inhibition of RICO up to a minimum of 18 hours.  
 
10.6 Analysis of Efficacy Parameters and Secondary Endpoints  
 
Descriptive statistics for efficacy parameters and secondary endpoints, including PD parameters, will be presented for all available data using either the ITT population, the safety  
population, or the PP population. The descriptive statistics will include (but not limited to) the number of observations, mean, standard deviation, median, minimum and maximum for continuous variables and number of observations and their percentages for categorical parameters. An SAP will be prepared before closing the database and will comprise all 
methods and tests applied for analysis of the data . 
 
10.7 Analysis of Tertiary and Exploratory Endpoints  
 
 
 
 
 
 
 
 
 
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013

Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 113/127  11. ETHICAL ISSUES AND I NSURANCE  
 
11.1 Independent Ethics Committee  
 
The study protocol (including all substantial amendments) together with the written informed consent form and informed consent updates, subject recruitment proc edures (e.g. 
advertisements), any other written information to be provided to subjects, and any other documents needed by [CONTACT_439958]. Written approval of the study needs to be obtained from the IEC prior to the start of the study.  
The Sponsor should submit written reports of the clinical study status to the IEC annually, or more frequently if requested by [CONTACT_6179]. A final study notification will be forwarded to the IEC 
within [ADDRESS_557781] of the Study  
 
The study will be conducted in accordance with the EU Clinical Trial Directive 2001/20/EC, 
the ICH guideline for GCP dated July 1996 and the ethical principles laid down in the Declaration of Helsinki ( Appendix 1). Current national regulations and guidelines will also be 
followed.  
 
11.[ADDRESS_557782] be approved 
(along with the protocol) by [CONTACT_439959]. The consent form must be in  a language fully comprehensible to the prospective subject/representative.  
In first intention, voluntary informed consent will be signed and dated by [CONTACT_439960] -Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 114/[ADDRESS_557783] will be able to provide consent according to local requirements, and regulations and IEC approval. In the clinical setting of this trial investigating the  acute phase of TTP, this occurrence is expected 
to be more frequent, with a more severe intensity of physical and/or mental incapacity. If 
local requirements, regulations and ethical committees allow, the study can be initiated prior 
to obtaining the informed consent, in case of physical or mental incapacity to consent and absence of a legal representative.  
As soon as possible, voluntary informed consent must be sought and obtained from these physically or mentally incapacitated subject, or legal representative, as applicable.  
It is the responsibility of the Investigator to assure that informed consent is obtained for each participant in accordance with Section 4.[ADDRESS_557784]’s medical records should also document that the informed consent form was signed and dated prior to any study -related procedures being performed.  
 
11.4 Insurance/Liability  
 All subjects who have given their written consent to the clinical study will be protected in accordance with local Law. The policies regarding compensation for injury for subjects are described in the compensation information leaflet and are available upon request. A copy of the compensation information leaflet will be given to the subject upon request in accordance with the country specific requirements.  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 115/127  12. GENERAL REGULATIONS,  AGREEMENTS AND 
ORGANISATIONAL PROCE DURES  
  
12.1 Legal Aspects/Declaration of Helsinki  
 
This study follows the Declaration of Helsinki (sixth revision, 2008) ( Appendix 1), the 
appropriate local regulations and the ICH -GCP Note for Guidance.  
 
12.2 Investigator’s Brochure  
 The Investigator will be informed about current knowledge concerning the study medication 
through the Investigator’s Brochure. Any substantial new information will be provided with no delay to all parties concerned.  
12.[ADDRESS_557785]’s initials.  
The Investigator ensures that the appointed monitor, the project manager, the auditor or 
representatives of the competent authorities and ECs may examine all parts of the documentation associated directly with this study (including,  but not limited to, laboratory test 
results, admission/discharge reports of hospi[INVESTIGATOR_439891]).  
 
12.4 Monitoring  
 During the study initiation visit the monitor explains to the Investigator all the documents and 
procedures relating to this study.  
Tight monitoring by [CONTACT_439961]’s high quality standards.  
A detailed description of monitoring is defined in the standard operating procedures (SOPs). Regular monitoring visits are carried out at appropriate intervals in order to clarify questions that may crop up and to review all CRFs in terms of completeness and plausibility. This also involves source data v erification.  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 116/127  The above includes a 100% review of subject numbers, initials, consent forms, demographic 
data, visit data, inclusion/exclusion criteria - as far as possible - as well as all AEs. The 
Investigator has to maintain these data up- to-date and well documented in the medical files.  
Source data verification is done by [CONTACT_439962].  
Personnel changes at the Investigator’s site and changes in responsibilities must be notified by [CONTACT_12552]/her immediately.  
The following is also constantly monitored: the study’s logistic workflow, compliance with regulations and the study medication’s handling.  
The monitor is the Investigator’s permanent contact [CONTACT_9702]. Unusual incidents will be 
documented immediately and forwarded to the project director.  
The remaining study medication and the CRFs will be retrieved on the clinical study’s 
completion.  
 
12.5 Audits and Inspections  
 
In the interests of quality assurance, the Sponsor or appointed independent experts may 
carry out audits during the clinical study’s implementation phase and after its completion. In conjunction with the audit it may also be examined whether the planning, implementation and analysis of the clinical study meets the relevant statutory regulations and the requirements of 
GCP. This includes a review of data maintenance and organisation at the study site and at the Sponsor’s, inspection of equipment and laboratories and of the source documents.  
 
12.6 Storage of Study Records in the Investigator’s File  
 The Investigator will be provided with an Investigator’s file. The Investigator will store those documents necessary for the clinical study. As part of the monitoring, the Investigator’s file will be inspected for up- to-date information and completeness in accordance with the 
national and international regulations.  
The Investigator records in the subject identification log the following details for all persons 
giving their consent to participate in the study: name (first and surname), date of birth, sex, 
subject initials (first and surname) and the assigned subject number. The date of recruitment into the study must also be documented.  
This subject identification log serves for later identification and remains with the Investigator.  
After the study’s completion or termination, all study documentation, including the subject identification log, will be properly archived in accordance with the Sponsor’s instructions.  
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 117/[ADDRESS_557786] parties. Employees participatin g in the 
study are bound by [CONTACT_439963].  
12.9 The Clinical Study’s Approval and General Obligation of Notification 
 All documents associated with the study will be submitted to the competent Regulatory Authority for approval.  
Additionally all notifications to local authorities as laid down in the relevant national regulations will be made.  
The Investigator will receive a copy of the notification for information.  
 
12.10  Final Report and Publication  
 
An integrated study report in accordance with the ICH Harmonised Tripartite Guideline (E3) 
(Structure and content of clinical study reports) will be prepared. The main clinical study 
report (CSR) will be generated once the last subject has completed the 1- month follow -up 
visit, and will describe the complete data set/results for the primary and secondary endpoints of all subjects in the trial. The data set/results on the 12- month follow -up period will be 
included in a longer term (disease outcome) addendum to the CSR.  
 All data and records provided by [CONTACT_99890] (other than subject’s medical records) and all data and inventions discovered in the course of conducting 
the study, whether patentable or not, are the sole and exclusive property of the Sponsor.  
The Investigator and all other study team members at any Service Provider involved will 
keep strictly confidential any information provided by [CONTACT_439964]: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 118/127  data and records generated in the course of the study. They will not use the information, data 
or records for any other purpose than conducting the study without prior written approval of 
the Sponsor.  
 Publication of any results from this study will be according to the principles of the Declaration of Helsinki, in particular point 30, and will require prior written agreement of the Sponsor.  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 119/127  13. REFERENCES  
 
 1.  Vesely S.K., George J.N., Lammle B.  et al.  ADAMTS13 activity in thrombotic 
thrombocytopenic purpura- hemolytic uremic syndrome: relation to presenting features 
and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60 -68. 
 2.  George J.N., Vesely S.K. and Terrell D.R. The Oklahoma Thrombotic 
Thrombocytopenic Purpura- Hemolytic Uremic Syndrome (TTP -HUS) Registry: a 
community perspective of patients with clinically diagnosed TTP -HUS. Semin.Hematol. 
2004; 41: 60 -67. 
 3.  Ulrichts Hans and Priem S. Internal report A068 -PHA-09-ANP-001: Assessment of in 
vitro potency of ALX -[ADDRESS_557787] in bioanalysis 
assays (draft study plan). 7 -9-2009.  
 4.  De Buck S. Internal report A001 -PHA-08-ISR-002: Plasma pharmacokinetics of 
ALX-0081 in the guinea pig after a single intravenous or subcutaneous administration. 
14-2- 2008.  
 5.  Leuschner J. and De Buck S. LPT report [ZIP_CODE]: Pharmacokinetic study  of ALX -0081 
following single intravenous or subcutaneous administration to guinea pi[INVESTIGATOR_14107]. 2008.  
 6.  Silence K. and Dreier T. Report ALX -0081 TR038: Clearance and biodistribution of 
ALX-0081, free or in complex with human vWF, evaluated in mice. 15- 12-2006.  
 7.  Laika B., Witschital K. and von Nieciecki A. BioProof report AB -08-01: Acute toxicity for 
ALX-0681 and ALX -0081 after respective single subcutaneous or intravenous 
administration to cynomolgus monkeys (LPT study [ZIP_CODE]/1). 14- 10-2008.  
 8.  Dreier T. Clinical study report ALX -0081 -01/06: A phase I, double -blind, randomized, 
placebo- controlled, parallel group study in healthy male volunteers to investigate the 
safety, tolerability and pharmacokinetics of the Nanobody ALX -0081 administered 
intravenously as single ascending doses. 20 -12-2007.  
 9.  Ohri M. Clinical study report ALX -0081- 1.2/08: A Phase I, double- blind, randomized, 
placebo- controlled study of ALX -0081 multiple dose administrations in stable angina 
patients undergoing percutaneous coronary intervention (PCI) Draft. 2-7- 2009.  
 10.  den Daas I. Clinical study report ALX -0681- 1.1/08 A phase I study in healthy volunteers 
to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of anti -
vWF Nanobody administered subcutaneously. 2-9-2009.  
 11.  Silence K. and Dreier T. Report ALX -0081 TR008: Bleeding risk assessment study with 
ALX-0081 in baboons and comparison with Plavix® and ReoPro®. 11 -11-2006.  
 12.  Mannucci P.M. Treatment of von Willebrand's disease. N.Engl.J.Med. 2004; 351:  683-
694. 
 13.  Allford S.L., Hunt B.J., Rose P. and Machin S.J. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br.J.Haematol. 2003; 120: 556 -573. Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 120/127   14.  Sadler J.E., Moake J.L., Miyata T. and George J.N. Recent advances in thrombotic 
thrombocytopenic purpura. Hematology.Am.Soc.Hematol.Educ.Program. 2004; , 407-
423. 
 15.  Martin J.N., Jr., Bailey A.P., Rehberg J.F.  et al.  Thrombotic thrombocytopenic purpura 
in 166 pregnancies: 1955- 2006. Am.J.Obstet.Gynecol. 2008; 199: 98 -104. 
 16.  Elliott M.A., Nichols W.L., Jr., Plumhoff E.A. et al.  Posttransplantation thrombotic 
thrombocytopenic purpura: a single- center experience and a contemporary review. 
Mayo Clin.Proc. 2003; 78: 421 -430. 
 17.  Kremer Hovinga J.A. and Meyer S.C. Current management of thrombotic 
thrombocytopenic purpura. Curr.Opin.Hematol. 2008; 15: 445 -450. 
 18.  Fontana S., Hovinga J.A., Studt J.D. et al. Plasma therapy in thrombotic 
thrombocytopenic purpura: review of the literature and the Bern experience in a 
subgroup of patients with severe acquired ADAMTS -13 deficiency. Semin.Hematol. 
2004; 41: 48 -59. 
 19.  George J.N. Evaluation and management of patients with thrombotic thrombocytopenic 
purpura. J.Intensive Care Med. 2007; 22: 82- 91. 
 20.  Howar d M.A., Williams L.A., Terrell D.R.  et al.  Complications of plasma exchange in 
patients treated for clinically suspected thrombotic thrombocytopenic purpura- hemolytic 
uremic syndrome. Transfusion 2006; 46: 154- 156. 
 21.  Rizvi M.A., Vesely S.K., George J.N . et al.  Complications of plasma exchange in 71 
consecutive patients treated for clinically suspected thrombotic thrombocytopenic 
purpura- hemolytic -uremic syndrome. Transfusion 2000; 40: 896- 901. 
 22.  Nguyen L., Terrell D.R., Duvall D., Vesely S.K. and George J.N. Complications of 
plasma exchange in patients treated for thrombotic thrombocytopenic purpura. IV. An 
additional study of 43 consecutive patients, 2005 to 2008. Transfusion 2009; 49: 392-
394. 
 23.  Lammle B., Kremer Hovinga J.A. and Alberio L. Thrombotic thrombocytopenic purpura. 
J.Thromb.Haemost. 2005; 3: 1663 -1675.  
 24.  Lewis Q.F., Lanneau M.S., Mathias S.D.  et al.  Long- term deficits in health- related 
quality of life after recovery from thrombotic thrombocytopenic purpura. Transfusion 
2009; 49: 118-124. 
 25.  Galbusera M., Benigni A., Paris S.  et al.  Unrecognized pattern of von Willebrand factor 
abnormalities in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. J.Am.Soc.Nephrol. 1999; 10: 1234- 1241.  
 26.  Remuzzi G., Galbusera M., Noris M. et al. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura 
and hemolytic uremic syndrome. Blood 2002; 100: 778 -785. 
 27.  Page L.K., Psaila B., Provan D. et al. The immune thrombocytopenic purpura (ITP) 
bleeding score: assessment of bleeding in patients with ITP. Br.J.Haematol. 2007; 138: 245-248. 
 28.  Bandarenko N., Brecher M.E. and Members of the US TT Apheresis Study Group. [LOCATION_002] Thrombotic Thrombocytopenic Purpura Apheresis Study group (US TTP Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 121/127  ASG): Multicenter survey and retrospective analysis of current efficacy of therapeutics 
plasma exchange. Journal of Clinical Apheresis 1998; 13: 133 -141. 
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 122/127  14. APPENDICES 
 
14.1 Appendix 1: Declaration of  Helsinki  
 
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI (Sixth revision, 2008)  
 Ethical Principles for Medical Research Involving Human Subjects  
Adopted by [CONTACT_941] 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended 
by [CONTACT_941] 
29th WMA Gener al Assembly, Tokyo, Japan, October [ADDRESS_557788], Republic of South Africa, October 1996 and the 52nd WMA General As sembly, Edinburgh, Scotland, October 2000  
53th WMA General Assembly, Washington 2002 (Note of Clarification on Paragraph  29 
added)  
55th WMA General Assembly, Tokyo 2004 (Note of Clarification on Paragraph 30 added)  
59th WMA General Assembly, Seoul, October 2008  
A. INTRODUCTION  
1. The World Medical Association (WMA) has developed the Declaration of Helsinki as a 
statement of ethical principles for medical research involving human subjects, including research on identifiable human material and data.  
The Declaration is intended to be read as a whole and each of its constituent 
paragraphs should not be applied without consideration of all other relevant 
paragraphs.  
2. Although the Declaration is addressed primarily to physicians, the WMA encourages other participants in medical research involving human subjects to adopt these principles.  
3. It is the duty of the physician to promote and safeguard the health of patients, including those who are involved in medical research. The physician's knowledge and conscience are dedicated to the fulfilment of this duty.  
4. The Declaration of Geneva of the WMA binds the physician with the words, "The health of my patient will be my first consideration," and the International Code of Medical Ethics declares that, "A physician shall act in the patient's best interest when 
providing medical care."  
5. Medical progress is based on research that ultimately must include studies involving 
human subjects. Populations that are underrepresented in medical research should be provided appropriate access  to participation in research.  
6. In medical research involving human subjects, the well -being of the individual 
research subject must take precedence over all other interests.  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 123/127  7. The primary purpose of medical research involving human subjects is to understand 
the causes, development and effects of diseases and improve preventive, diagnostic and therapeutic interventions (methods, procedures and treatments). Even the best current interventions must be evaluated continually through research for their safety, effectiveness, efficiency, accessibility and quality.  
8. In medical practice and in medical research, most interventions involve risks and 
burdens.  
9. Medical research is subject to ethical standards that promote respect for all human 
subjects and protect their health and rights. Some research populations are particularly vulnerable and need special protection. These include those who cannot give or refuse consent for themselves and those who may be vulnerable to coercion 
or undue influence.  
10. Physicians should consider the ethical, legal and regulatory norms and standards for 
research involving human subjects in their own countries as well as applicable international norms and standards. No national or international ethical, legal or regulatory requirement should reduce or eliminate any of the protections for research subjects set forth in this Declaration.  
B. BASIC PRINCIPLES FOR ALL MEDICAL RESEARCH  
11. It is the duty of physicians who participate in medical research to protect the life, 
health, dignity, integrity, right to  self-determination, privacy, and confidentiality of 
personal information of research subjects.  
12. Medical research involving human subjects must conform to generally accepted 
scientific principles, be based on a thorough knowledge of the scientific literatur e, 
other relevant sources of information, and adequate laboratory and, as appropriate, 
animal experimentation. The welfare of animals used for research must be respected.  
13. Appropriate caution must be exercised in the conduct of medical research that may 
harm the environment.  
14. The design and performance of each research study involving human subjects must be clearly described in a research protocol. The protocol should contain a statement of the ethical considerations involved and should indicate how the principles in this 
Declaration have been addressed. The protocol should include information regarding 
funding, sponsors, institutional affiliations, other potential conflicts of interest, incentives for subjects and provisions for treating and/or compensating subjects who 
are harmed as a consequence of participation in the research study. The protocol should describe arrangements for post -study access by [CONTACT_439965].  
15. The research protocol must be submitted for consideration, comment, guidance and approval to a research ethics committee before the study begins. This committee must be independent of the researcher, the sponsor and any other undue influence. It  
must take into consideration the laws and regulations of the country or countries in 
which the research is to be performed as well as applicable international norms and 
standards but these must not be allowed to reduce or eliminate any of the protections for research subjects set forth in this Declaration. The committee must have the right to monitor ongoing studies. The researcher must provide monitoring information to the committee, especially information about any serious adverse events. No change to the protocol may be made without consideration and approval by [CONTACT_942].  
16. Medical research involving human subjects must be conducted only by [CONTACT_62383]. Research on patients or healthy volunteers requires the supervision of a competent and appropriately qualified physician or other health care professional. The responsibility for the protection of research subjects must always rest with the physician or other health care professional and never the research subjects, even though they have given consent.  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 124/[ADDRESS_557789]'s 
freely -given informed consent, preferably in writing. If the consent cannot be 
expressed in writing, the non- written consent must be formally documented and 
witnessed.  
25. For medical research using identifiable human material or data, physicians must 
normally seek consent for the collection, analysis, storage and/or reuse. There may be situations where consent would be impossible or impractical to obtain for such 
research or would pose a threat to the validity of the research. In such situations the 
research may be done only after consideration and approval of a research ethics committee.  
26. When seeking informed consent for participation in a research study the physician 
should be particularly cautious if the potential subject is in a dependent relationship with the physician or may consent under duress. In such situations the informed 
consent should be sought by [CONTACT_163050].  
27. For a potential research subject who is incompetent, the physician must seek informed consent from the legally authorized representative. These individuals must not be included in a research study  that has no likelihood of benefit for them unless it 
is intended to promote the health of the population represented by [CONTACT_62386], the research cannot instead be performed with competent persons, and the 
research entails only minimal risk and minimal burden.  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 125/[ADDRESS_557790]'s dissent should be respected.  
29. Research involving subjects who are physically or mentally incapable of giving consent, for example, unconscious patients, may be done only if the physical or 
mental condition that prevents giving informed consent is a necessary characteristic of 
the research population. In such circumstances the physician should seek informed consent from the legally authorized representative. If no such representative is available and if the research cannot be delayed, the study may proceed without informed consent provided that the specific reasons for involving subjects with a 
condition that renders them unable to give informed consent have been stated in the 
research protocol and the study has been approved by a research et hics committee. 
Consent to remain in the research should be obtained as soon as possible from the subject or a legally authorized representative.  
30. Authors, editors and publishers all have ethical obligations with regard to the publication of the results of research. Authors have a duty to make publicly available 
the results of their research on human subjects and are accountable for the 
completeness and accuracy of their reports. They should adhere to accepted guidelines for ethical reporting. Negative and inconclusive as well as positive results should be published or otherwise made publicly available. Sources of funding, institutional affiliations and conflicts of interest should be declared in the publication. Reports of research not in accordance with the principles of this Declaration should 
not be accepted for publication.  
C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH 
MEDICAL CARE  
31. The physician may combine medical research with medical care only to the extent that 
the research is justified by [CONTACT_151084], diagnostic or therapeutic value and 
if the physician has good reason to believe that participation in the research study will not adversely affect the health of the patients who serve as research subjects.  
32. The benefits, risks, burdens and effectiveness of a new intervention must be tested against those of the best current proven intervention, except in the following circumstances:  
• The use of placebo, or no treatment, is acceptable in studies where no current proven intervention exi sts; or  
• Where for compelling and scientifically sound methodological reasons the use of 
placebo is necessary to determine the efficacy or safety of an intervention and the 
patients who receive placebo or no treatment will not be subject to any risk of ser ious 
or irreversible harm. Extreme care must be taken to avoid abuse of this option.
 
33. At the conclusion of the study, patients entered into the study are entitled to be 
informed about the outcome of the study and to share any benefits that result from it, 
for example, access to interventions identified as beneficial in the study or to other 
appropriate care or benefits.  
34. The physician must fully inform the patient which aspects of the care are related to the research. The refusal of a patient to participate in a study or the patient's decision to withdraw from the study must never interfere with the patient -physician relationship.  
35. In the treatment of a patient, where proven interventions do not exist or have been ineffective, the physician, after seeking expert advice, with informed consent from the patient or a legally authorized representative, may use an unproven intervention if in the physician's judgement it offers hope of saving life, re- establishing health or 
alleviating suffering. Where possible, this intervention should be made the object of research, designed to evaluate its safety and efficacy. In all cases, new information 
should be recorded and, where appropriate, made publicly available.  
22.10.2008  Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 126/127  14.2 Appendix 2: Common Term inology for Adverse Events v4.0 
(CTCAE)  
 
National Cancer Institute (NCI) CTCAE Version 4.0 
See http://ctep.cancer.gov/reporting/ctc.html . 
 
14.3 Appendix 3: Elements of Informed Consent  
 
The following elements of Informed Consent are compatible with the ICH, GCP and country -
specific  regulations. The Informed Consent Form should address each issue listed.  
 
1. The trial involves research.  
2. The purpose of the trial.  
3. The trial treatment(s) and the probability for random assignment to each treatment.  
4. The trial procedures to be followed, including all invasive procedures.  
5. The subject’s responsibilities.  
6. Those aspects of the trial that are experimental.  
7. The reasonably foreseeable risks or inconveniences to the subject and, when applicable, to an embryo, foetus, or nursing infant.  
8. The reasonably expected benefits. When there is no intended clinical benefit to the subject, the subject should be made aware of this.  
9. The alternative procedure(s) or course(s) of treatment that may be available to the subject, and their important benefits and risks.  
10. The compensation and/or treatment available to the subject in the event of a trial -related injury.  
11. The anticipated prorated payment, if any, to the subject for participating in the trial.  
12. The anticipated expenses, if any, to the subject for participating in the trial.  
13. The subject’s participation in the trial is voluntary and that the subject may refuse to participate or withdraw from the trial, at any time, without penalty or loss of benefits to which the subject is otherwise entitled.  
14. The monitors, the auditors, the IRB/IEC and the regulatory authorities will be granted direct access to the subject’s original medical records for verification of clinical trial procedures and/or data, without violating the confidentiality of the subject, to the extent permitted by [CONTACT_120938], by [CONTACT_8753], the subject or the subject’s legally acceptable 
representatives authorise such access . 
15. Records identifying the subject will be kept confidential and, to the extent permitted by [CONTACT_3999]/or regulations, will not be made publicly available. If the results of the trial are 
published, the subject’s identity will remain confident ial. Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
Ablynx NV  Clinical Study Protocol  Study ALX -0681- 2.1/10  
June 24, 2013  CONFIDENTIAL   Page 127/[ADDRESS_557791]’s legally acceptable representative will be informed in a timely manner 
if information becomes available that may be relevant to the subject’s willingness to continue participation in the trial.  
17. The person(s) to contact [CONTACT_439966], 
and whom to contact [CONTACT_99822] -related injury.  
18. The foreseeable circumstances and/or reasons under which the subject’s participation in the trial 
may be terminated.  
19. The expected duration of the subject’s participation in the trial.  
20. The approximate number of subjects involved in the trial.  
 Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/[ADDRESS_557792] that was signed electronically in Livelink. 
This page is the manifestation of the electronic signature(s) used in compliance with the organizations 
electronic signature [CONTACT_13695].  
 
Date: Monday, 08 July 2013, 10:51   Romance Daylight Time 
Meaning: Approved 
================================================Document ID: 25_A0068_13_0076          ADMS Version Number: 1.0          Printing Date: 08/Aug/2013
